Pituitary Diseases and Bone
Open accessAbstract
Neuroendocrinology of bone is a new area of research based on the evidence that pituitary hormones may directly modulate bone remodeling and metabolism. Skeletal fragility associated with high risk of fractures is a common complication of several pituitary diseases such as hypopituitarism, Cushing disease, acromegaly, and hyperprolactinemia. As in other forms of secondary osteoporosis, pituitary diseases generally affect bone quality more than bone quantity, and fractures may occur even in the presence of normal or low-normal bone mineral density as measured by dual-energy X-ray absorptiometry, making difficult the prediction of fractures in these clinical settings. Treatment of pituitary hormone excess and deficiency generally improves skeletal health, although some patients remain at high risk of fractures, and treatment with bone-active drugs may become mandatory. The aim of this review is to discuss the physiological, pathophysiological, and clinical insights of bone involvement in pituitary diseases.
AI snapshot
Written from the paper’s full text.
TL;DR
Pituitary hormone excess or deficiency commonly causes skeletal fragility, often with fractures despite normal or low-normal bone mineral density by DXA. This narrative review synthesizes mechanisms and clinical evidence across acromegaly, prolactinoma, Cushing disease, TSH-oma, and hypopituitarism, emphasizing morphometric vertebral assessment and the limits of BMD for fracture prediction.
Key findings
- Vertebral fractures are a frequent complication of pituitary diseases; DXA does not reliably predict fracture risk, and morphometric vertebral assessment is currently the mainstay for skeletal evaluation.
- In acromegaly, the overall median prevalence of vertebral fractures is ~40%, with fracture risk threefold to eightfold higher than controls; a prospective study found incident vertebral fractures in 42% of patients over 3 years, related to active disease and duration.
- In prolactinoma, radiological vertebral fractures occurred in 32.6% of women (25/78) and 37.5% of men; 80% of male patients had osteopenia or osteoporosis at the lumbar spine, whereas only 30% had low femoral neck BMD.
- In Cushing disease, DXA osteoporosis prevalence is 28% to 50%, fracture prevalence 15% to 50%, and morphometric vertebral fracture prevalence 78%; in growth hormone deficiency, fracture risk is twofold to fivefold higher, more than 60% of adults had vertebral fractures in one study, and after 6 years untreated GHD had a sevenfold higher risk of vertebral fractures than treated GHD.
Methods
- Narrative review of physiological, pathophysiological, and clinical literature on bone involvement in pituitary diseases, including hypopituitarism, Cushing disease, acromegaly, and hyperprolactinemia.
- Synthesizes experimental, observational, cross-sectional, prospective, and meta-analytic evidence; includes tables of studies evaluating fragility fractures and bone structure in acromegaly, prolactinoma, Cushing disease, and hypopituitarism.
- No new primary patient data or systematic review methodology are reported.
Limitations
- Stated: no specific guidelines have been published on monitoring skeletal health in pituitary diseases, so monitoring cannot be evidence based; no randomized controlled trials evaluate rhGH effects on fracture risk; no studies have tested antiosteoporotic drugs in acromegaly; clinical relevance of IGFBP skeletal effects and FSH effects in humans remains unclear.
- Evident from the text: as a narrative review, it does not use a systematic search or formal meta-analysis, and many cited fracture studies are cross-sectional or retrospective, with heterogeneous designs and endpoints.
- Evident from the text: DXA limitations are repeatedly noted, including inability to capture bone quality, microstructure, and compartment-specific changes, which affects fracture prediction in these populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
2 of 135 cited sources checked · 2 supported · 0 flagged
- Premisecitation
In igfbp-4-null female mice, cortical area fraction and cortical thickness at the femur midshaft are significantly reduced.
“Significant reductions were also observed in cortical area fraction and cortical thickness at the femur midshaft.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [155] Maridas, 2017, IGFBP-4 regulates adult skeletal growth in a sex-specific manner, J Endocrinol source
- Premisecitation
In this study baseline TBS was normal.
“However, in this study baseline TBS was normal.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [449] Allo Miguel, 2016, Seven years of follow up of trabecular bone score, bone mineral density, body composition and quality of life in adults with growth hormone deficiency treated with rhGH replacement in a single center, Ther Adv Endocrinol Metab source
- Study design and conductcitation
Questionnaires and databases cannot correctly identify vertebral fractures.
“likely reflecting the impossibility of questionnaires and databases to correctly identify VFs ().”
Quote in the paperSubstantial claim - Interpretationreasoning
Increased bone formation seen in vivo is likely due to coupling of bone formation to bone resorption, which is absent in in vitro conditions.
“Increased bone formation seen in vivo was likely due to the coupling of bone formation to bone resorption, which was absent in in vitro conditions.”
Quote in the paperSubstantial claim - Premisecitation
Despite the stimulating effects of GH and IGF-I on renal activation of vitamin D, hypovitaminosis D has been consistently reported in patients with acromegaly.
“Despite the stimulating effects of GH and IGF-I on renal activation of vitamin D (), hypovitaminosis D has been consistently reported in patients with acromegaly (, ), and there is also evidence suggesting lower peripheral bioavailability of vitamin D in this clinical setting as an effect of an increase in vitamin D binding protein (, ).”
Quote in the paperNot a substantial claim
- Interpretationreasoning
The effects of PTH on the RANKL-OPG axis may explain the differential effect of short versus prolonged exposure to PTH on the balance of its anabolic and catabolic actions.
“These effects on the RANKL-OPG axis may explain the differential effect of short vs prolonged exposure to PTH with respect to the balance of its anabolic and catabolic actions.”
Quote in the paperSubstantial claim - Interpretationnone given
Current experimental observations suggest that most of the effects of GH on bone are mediated by IGF-I.
“In summary, the current experimental observations suggest that most of the effects of GH on bone are mediated by IGF-I.”
Quote in the paperSubstantial claim - Interpretationnone given
There is growing evidence that pituitary hormones may bypass traditional endocrine organs to exert direct effects on the skeleton.
“However, there has been growing evidence to suggest that pituitary hormones may bypass traditional endocrine organs to exert remarkable direct effects on the skeleton.”
Quote in the paperNot a substantial claim - Premisecitation
In several clinical studies, serum TSH values in the reference range were associated with BMD and fractures.
“In several clinical studies, serum TSH values in the reference range were associated with BMD and fractures.”
Quote in the paperSubstantial claim - Premisenone given
Dual-energy X-ray absorptiometry measurement of bone mineral density does not provide information on bone quality, which depends on bone macrostructure, microstructure, mineralization, microdamage, and collagen status.
“In fact, DXA measurement of BMD does not provide information on bone quality, which depends on bone macrostructure, microstructure, mineralization, microdamage, and collagen status.”
Quote in the paperSubstantial claim - Interpretationreasoning
Vertebral fractures possibly contribute to kyphosis of patients with acromegaly.
“possibly contributing to kyphosis of patients with acromegaly, a feature clearly present in the first patients reported by Pierre-Marie ().”
Quote in the paperNot a substantial claim - Premisecitation
GH excess influences PTH pulsatility with prolongation of pulse half-duration and increase in pulse mass.
“Moreover, GH excess was shown to influence PTH pulsatility with prolongation of pulse half-duration and increase in pulse mass ().”
Quote in the paperNot a substantial claim - Premiseown data
In patients with acromegaly, vertebral fractures were shown to be slightly more frequent in males as compared with females.
“VFs were shown to be slightly more frequent in males as compared with females (Fig. ).”
Quote in the paperNot a substantial claim - Premisecitation
In a retrospective longitudinal study, Battista et al. reported incident vertebral fractures in more than a third of acromegaly patients with hypogonadism regardless of activity of disease.
“In a retrospective longitudinal study, Battista et al. () reported incident VFs in more than a third of acromegaly patients with hypogonadism regardless of activity of disease.”
Quote in the paperNot a substantial claim - Premisecitation
Using HR-pQCT, Madeira et al. reported significant associations between several parameters of bone microstructure and either gonadal or activity of disease in 82 patients with acromegaly.
“Using HR-pQCT, Madeira et al. () reported significant associations between several parameters of bone microstructure (i.e., BV/TV, Tb.N, and mean trabecular separation) and either gonadal or activity of disease in patients with acromegaly ( males, females).”
Quote in the paperSubstantial claim - Premisecitation
Such an association was shown to be independent of thyroid hormone values.
“Such an association was shown to be independent of thyroid hormone values.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [270] Mazziotti, 2010, Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density, Bone source
- Premisenone given
IGF-I is the mediator of most effects of GH on peripheral tissues.
“IGF-I is the mediator of most effects of GH on peripheral tissues.”
Quote in the paperNot a substantial claim - Premisecitation
Retrospective studies did not show an increased clinical fracture risk in acromegaly.
“Retrospective studies did not show an increased clinical fracture risk in acromegaly (, ), likely reflecting the impossibility of questionnaires and databases to correctly identify VFs ().”
Quote in the paperSubstantial claim - Study design and conductreasoning
DXA measurements of BMD in acromegaly may be affected by pitfalls related to the abnormalities of bone structure caused by GH hypersecretion.
“DXA measurements of BMD in acromegaly may be affected by some pitfalls related to the abnormalities of bone structure caused by GH hypersecretion.”
Quote in the paperSubstantial claim - Premisecitation
Patients with acromegaly have increased bone turnover, as determined by changes in biochemical markers, calcium kinetics, and bone histomorphometry.
“Patients with acromegaly have increased bone turnover, as determined by changes in biochemical markers, calcium kinetics, and bone histomorphometry ().”
Quote in the paperSubstantial claim - Interpretationcitation
A high prevalence and incidence of vertebral fractures is related to increased bone turnover and deterioration of bone structure.
“In the last few years, it has clearly emerged that a high prevalence and incidence of VFs is related to increased bone turnover and deterioration of bone structure, although evidence that acromegaly may cause impairment in bone quality was already provided by Ueland et al. () in : they reported loss of trabecular connections and low trabecular bone biomechanical competence in iliac crest bi”
Quote in the paperSubstantial claim - Interpretationreasoning
Experimental models provide evidence that the direct skeletal effects of FSH may be influenced by gonadal function because severe hypoestrogenemia would invariably prevent full osteoprotection by FSH inhibition.
“However, the experimental models also provided evidence that the direct skeletal effects of FSH may be influenced by the gonadal function because severe hypoestrogenemia would invariably prevent full osteoprotection by FSH inhibition.”
Quote in the paperSubstantial claim - Premisenone given
Bone loss has been sporadically reported in hyperthyroid patients with TSH-secreting adenoma (TSH-oma), despite normal or even high TSH values.
“Likewise, bone loss has been sporadically reported in hyperthyroid patients with TSH-secreting adenoma (TSH-oma), despite normal or even high TSH values”
Quote in the paperNot a substantial claim - Interpretationcitation
Pituitary diseases generally affect bone quality more than bone quantity.
“pituitary diseases generally affect bone quality more than bone quantity”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] Mazziotti, 2015, Pituitary diseases and bone, Endocrinol Metab Clin North Am source
- Interpretationcitation
There is evidence that TSH may have direct effects on skeletal remodeling in humans, such as previously demonstrated in experimental animals.
“There is evidence that TSH may have direct effects on skeletal remodeling in humans, such as previously demonstrated in experimental animals.”
Quote in the paperSubstantial claim - Interpretationcitation
That more than 50% of patients with fractures were shown to have either multiple or severe vertebral fractures suggests that vertebral fractures may be associated with an unfavorable functional outcome.
“However, that .% of patients with fractures were shown to have either multiple or severe VFs () suggests that VFs may be associated with an unfavorable functional outcome (), such as demonstrated in other clinical settings (-).”
Quote in the paperNot a substantial claim - Interpretationreasoning
Experimental data suggest that FSH stimulates osteoclastogenesis and bone resorption.
“In summary, experimental data suggest that FSH stimulates osteoclastogenesis and bone resorption.”
Quote in the paperSubstantial claim - Interpretationreasoning
Some clinical studies evaluating skeletal endpoints in patients with prolactinoma suggest that PRL may have a direct effect on bone in humans, such as demonstrated in experimental models.
“However, some clinical studies evaluating the skeletal endpoints in patients with prolactinoma seem to suggest that PRL may have a direct effect on bone in humans, such as demonstrated in experimental models”
Quote in the paperNot a substantial claim - Interpretationnone given
Pituitary hormones may directly modulate bone remodeling and metabolism.
“Neuroendocrinology of bone is a new area of research based on the evidence that pituitary hormones may directly modulate bone remodeling and metabolism.”
Quote in the paperNot a substantial claim - Premisecitation
Our group reported vertebral fractures in 23 out of 40 male patients with acromegaly (median age 47 years).
“Three years later, our group also reported VFs in out of male patients with acromegaly (median age years) ().”
Quote in the paperNot a substantial claim - Interpretationcitation
Differences between lumbar spine and femoral neck BMD may be influenced by the activity of acromegaly, reflecting the different effects of GH excess on trabecular and cortical bone.
“Moreover, the differences between lumbar spine and femoral neck BMD may be also influenced by the activity of acromegaly, reflecting the different effects of GH excess on trabecular and cortical bone ().”
Quote in the paperSubstantial claim - Premisecitation
In studies evaluating both processes of bone remodeling, the differences in bone resorption were higher than those observed for bone formation.
“In studies evaluating both processes of bone remodeling, the differences in bone resorption were higher than those observed for bone formation (, , , , , ), supporting the concept that bone loss occurs in acromegaly as an effect of uncoupled bone turnover ().”
Quote in the paperSubstantial claim - Premisecitation
In cross-sectional studies of acromegaly, the rate of fractures was found to be relatively increased in hypogonadal as compared with eugonadal patients.
“Moreover, in five cross-sectional studies including patients with acromegaly ( patients with hypogonadism, with active disease), as already reported in other forms of secondary osteoporosis (), the rate of fractures was found to be relatively increased in hypogonadal as compared with eugonadal patients (, , , , ).”
Quote in the paperNot a substantial claim - Premisecitation
Fractures were multiple in more than two-thirds of women with fractures.
“Fractures were multiple in more than twothirds of women with fractures.”
Quote in the paperNot a substantial claim - Premisecitation
There is evidence suggesting lower peripheral bioavailability of vitamin D in acromegaly as an effect of an increase in vitamin D binding protein.
“there is also evidence suggesting lower peripheral bioavailability of vitamin D in this clinical setting as an effect of an increase in vitamin D binding protein (, ).”
Quote in the paperNot a substantial claim - Study design and conductcitation
Joint degenerative disorders, characterized by osteophyte formation and facet joint hypertrophy, may lead to an overestimation of BMD measured at the lumbar spine in acromegaly.
“Joint degenerative disorders, characterized by osteophyte formation and facet joint hypertrophy, may lead to an overestimation of BMD measured at the lumbar spine ().”
Quote in the paperSubstantial claim - Premisereasoning
Loss of sex steroids increases bone turnover at the trabecular level, which is predominant in the spine.
“consistent with the concept that loss of sex steroids increases bone turnover at the trabecular level, which is predominant in the spine.”
Quote in the paperSubstantial claim - Interpretationreasoning
Bone loss occurs in acromegaly as an effect of uncoupled bone turnover.
“supporting the concept that bone loss occurs in acromegaly as an effect of uncoupled bone turnover ().”
Quote in the paperSubstantial claim - Premisecitation
Many limitations of areal dual-energy X-ray absorptiometry measurement can be overcome by performing high-resolution peripheral quantitative CT at the distal radius and tibia.
“Many of the limitations of areal DXA measurement can be overcome by performing high-resolution peripheral quantitative CT (HR-pQCT) at the distal radius and tibia.”
Quote in the paperNot a substantial claim - Premisenone given
No direct effects of PRL on osteoclasts have been demonstrated.
“No direct effects of PRL on osteoclasts were demonstrated.”
Quote in the paperNot a substantial claim - Premisecitation
A recent retrospective study reported a higher incidence of vertebral fractures in patients with active acromegaly regardless of the therapeutic approach.
“This study reported a higher incidence of VFs in patients with active disease regardless of the therapeutic approach ().”
Quote in the paperSubstantial claim - Premisecitation
In hypogonadal patients with acromegaly, BMD was low at the lumbar spine and to a lesser extent at the femoral neck.
“Indeed, when the analysis was performed in hypogonadal patients (, , , -), BMD was low at the lumbar spine and to a lesser extent at the femoral neck (), consistent with the concept that loss of sex steroids increases bone turnover at the trabecular level, which is predominant in the spine.”
Quote in the paperSubstantial claim - Premisecitation
Ueland et al. reported loss of trabecular connections and low trabecular bone biomechanical competence in iliac crest biopsies of 13 acromegaly patients with active acromegaly.
“they reported loss of trabecular connections and low trabecular bone biomechanical competence in iliac crest biopsies of acromegaly patients ( males and females) with active acromegaly.”
Quote in the paperSubstantial claim - Interpretationreasoning
Hypercalciuria may be considered, at least in part, as a marker of skeletal fragility.
“Therefore, hypercalciuria may be considered, at least in part, as a marker of skeletal fragility.”
Quote in the paperSubstantial claim - Premisecitation
The biochemical skeletal phenotype in endogenous hypercortisolism may be characterized by uncoupled low bone formation and slightly increased bone resorption.
“However, the biochemical skeletal phenotype may be characterized by uncoupled low bone formation and slightly increased bone resorption (-).”
Quote in the paperNot a substantial claim - Premisecitation
In ACTH-independent hypercortisolism, abnormalities of bone microstructure are predictive of incident vertebral fractures.
“in ACTH-independent hypercortisolism abnormalities of bone microstructure were shown to be predictive of incident VFs ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In a prospective study, acromegaly patients experiencing incident vertebral fractures had significant reduction in femoral neck BMD during follow-up.
“patients experiencing incident VFs were shown to have significant reduction in BMD at femoral neck during follow-up ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In Cushing's disease, lumbar spine BMD is an important predictor of fractures in untreated and treated patients.
“lumbar spine BMD was shown to be an important predictor of fractures in untreated () and treated CD ().”
Quote in the paperSubstantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Two recent cross-sectional studies reported high prevalence of radiological vertebral fractures in women and men with PRL-oma.
“Two recent cross-sectional studies reported high prevalence of radiological VFs in women and men with PRL-oma (, ).”
Quote in the paperSubstantial claim - Premisecitation
When acromegaly is controlled, no significant difference in incident vertebral fractures is observed between pegvisomant and SRLs.
“When acromegaly was controlled, no significant difference in incident VFs was observed between pegvisomant and SRLs ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Fractures are threefold more frequent in patients with persistently active acromegaly as compared with those in whom acromegaly is controlled by treatment.
“the fractures are threefold more frequent in patients with persistently active disease as compared with those in whom acromegaly is controlled by the treatment (-, , ).”
Quote in the paperSubstantial claim0 of 3 sources checked- cites -
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Twenty-two percent of premenopausal women with PRL-oma showed a pathological z score with more severe bone loss at lumbar spine as compared with femoral DXA sites.
“Twenty-two percent of premenopausal women with PRL-oma showed a pathological z score (i.e., a z score #2.SD) with more severe bone loss at lumbar spine as compared with femoral DXA sites ().”
Quote in the paperNot a substantial claim - Premisecitation
In PRL-oma, the association between lower lumbar spine BMD and fractures is lost after adjustment for duration of disease.
“although such an association was lost after adjustment for duration of disease ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Pasireotide normalizes urinary cortisol values in 17% to 20% of patients with Cushing's disease.
“Pasireotide normalized urinary cortisol values in % to % of patients with CD (, ).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Prevalent vertebral fractures are a marker of skeletal fragility predisposing patients to develop other fractures, even when mild in severity.
“prevalent VFs, which are a marker of skeletal fragility () predisposing patients to develop other fractures (), even when VFs are mild in severity ().”
Quote in the paperSubstantial claim0 of 3 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The concept that prevalent vertebral fractures predispose to other fractures has been confirmed in pituitary diseases by prospective studies in acromegaly or GHD.
“This concept has been confirmed even in the specific setting of pituitary diseases by few prospective studies performed in patients with acromegaly (, ) or GHD ().”
Quote in the paperSubstantial claim0 of 3 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Several other studies reported a significant association between BMD values and hypogonadism in patients with PRL-oma.
“In contrast, several other studies reported a significant association between BMD values and hypogonadism in patients with PRL-oma (, , -).”
Quote in the paperNot a substantial claim - Premisecitation
Silva et al. reported deterioration in trabecular microstructure of the radius in 16 eugonadal males with acromegaly.
“This concept was recently reinforced by Silva et al. (), who reported deterioration in trabecular microstructure of the radius in eugonadal males with acromegaly.”
Quote in the paperSubstantial claim - Interpretationreasoning
PRL excess per se may cause skeletal fragility regardless of gonadal status.
“These findings suggested that PRL excess per se may cause skeletal fragility regardless of gonadal status, although the cross-sectional design did not allow defining exactly when VFs developed in relationship with menopausal status ().”
Quote in the paperSubstantial claim - Study design and conductreasoning
The cross-sectional design did not allow defining exactly when vertebral fractures developed in relationship with menopausal status.
“although the cross-sectional design did not allow defining exactly when VFs developed in relationship with menopausal status ().”
Quote in the paperSubstantial claim - Premisecitation
Pasireotide LAR normalizes GH and IGF-I values in 20% of patients not responding to first-generation SRLs.
“Pasireotide LAR is a multireceptortargeted SRL that was shown to normalize GH and IGF-I values in % of patients not responding to first-generation SRLs ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Fractionated radiotherapy and stereotactic radiosurgery have comparable efficacy and safety.
“The two approaches were shown to have comparable efficacy and safety ()”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationnone given
Patients with pituitary diseases without prevalent vertebral fractures and without densitometric osteoporosis may still develop fragility fractures.
“Patients affected by pituitary diseases, without prevalent VFs and densitometric diagnosis of osteoporosis, may still develop fragility fractures.”
Quote in the paperSubstantial claim - Interpretationcitation
In endogenous hypercortisolism, the early and transient phase of high bone turnover is not usually evident because the diagnosis of disease is often delayed with respect to onset of hypercortisolism.
“Differently from exogenous glucocorticoid excess (), in endogenous hypercortisolism the early and transient phase of high bone turnover is not usually evident because the diagnosis of disease is often delayed with respect to onset of hypercortisolism ().”
Quote in the paperNot a substantial claim - Interpretationreasoning
In patients with persisting active acromegaly, DXA measurement of BMD is of limited reliability in predicting fractures.
“DXA measurement of BMD is of limited reliability in predicting fractures when patients have persisting active disease.”
Quote in the paperSubstantial claim - Premisecitation
First-generation somatostatin receptor ligands (octreotide LAR and lanreotide autogel) are the first-line medical therapy of acromegaly either when surgery fails to control GH/IGF-I hypersecretion or as first-line therapy in patients with a low probability of surgical cure.
“First-generation somatostatin receptor ligands (SRLs), octreotide long-acting repeatable (LAR) and lanreotide autogel, are the first-line medical therapy of acromegaly either when surgery fails to control GH/ IGF-I hypersecretion or as first-line therapy in patients with a low probability of surgical cure (, , ).”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
In acromegaly, vertebral fractures often occur in the presence of normal or even high BMD.
“VFs often occur in the presence of normal or even high BMD”
Quote in the paperSubstantial claim - Premisecitation
The Prolactin Epidemiology, Audit and Research Study did not find a significant increase in fractures in patients with PRL-oma.
“Using the International Classification of Diseases codes, the Prolactin Epidemiology, Audit and Research Study did not find a significant increase in fractures in patients with PRL-oma, suggesting that this complication could be underestimated in real-life clinical practice ().”
Quote in the paperSubstantial claim - Premisecitation
In cross-sectional and prospective studies, biochemical control of acromegaly is associated with a decrease in serum levels of biochemical markers of bone turnover.
“In cross-sectional and prospective studies, biochemical control of acromegaly was associated with a decrease in serum levels of biochemical markers of bone turnover (, , , , , , ).”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
When DXA BMD shows either a decrease or an absolute value in the osteoporosis range, the risk of fractures is high.
“when DXA measurements of BMD report either a decrease of BMD values or an absolute BMD value in the range of osteoporosis, the risk of fractures is high.”
Quote in the paperSubstantial claim - Interpretationcitation
Structural properties of trabecular and cortical bone may be persistently deteriorated after reversal of GH hypersecretion.
“structural properties of trabecular and cortical bone may be persistently deteriorated after reversal of GH hypersecretion”
Quote in the paperSubstantial claim - Premisecitation
In Cushing's disease, nearly a third of patients experience long-term failure of surgery and require additional second-line treatment.
“In CD, nearly a third of patients experience in the long-term a failure of surgery and require an additional second-line treatment ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In Cushing's disease, a remarkable number of patients may fracture in the presence of low-normal or even normal BMD values.
“a remarkable number of patients with CD may fracture in the presence of low-normal or even normal BMD values (-, ).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites -
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
Compromised bone microstructure in acromegaly may occur regardless of gonadal status.
“supporting the hypothesis that compromised bone microstructure in acromegaly may occur regardless of gonadal status ().”
Quote in the paperSubstantial claim - Premisecitation
In untreated GHD, vertebral fractures occur also in a significant percentage of patients with normal BMD.
“VFs occurred also in a significant percentage of patients with normal BMD ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
Normal or low-normal BMD does not exclude that patients may develop fractures.
“the finding of normal or low-normal BMD does not exclude that patients may develop fractures.”
Quote in the paperSubstantial claim - Premisereasoning
In active acromegaly, untreated hypogonadism and diabetes mellitus do not significantly impact the risk of vertebral fractures.
“both the clinical conditions did not significantly impact the risk of VFs when acromegaly was active”
Quote in the paperSubstantial claim - Premisecitation
Normalization of IGF-I values occurs in 60% to 80% of acromegaly patients treated with pegvisomant.
“Normalization of IGF-I values occurs in % to % of acromegaly patients treated with pegvisomant (, ).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Vestergaard et al. reported a 60% increase in risk of clinical fractures in PRL-oma before the diagnosis of disease as compared with controls.
“In contrast, Vestergaard et al. () reported a % increase in risk of clinical fractures in PRL-oma before the diagnosis of disease as compared with controls.”
Quote in the paperNot a substantial claim - Premisecitation
SRLs and pegvisomant may have pleiotropic effects on peripheral targets of acromegaly with potential improvement of clinical endpoints regardless of the achievement of strict biochemical control of disease.
“There is evidence that SRLs and pegvisomant may have pleiotropic effects on peripheral targets of acromegaly with potential improvement of clinical endpoints regardless of the achievement of a strict biochemical control of disease (, , ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, , )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Men and women with PRL-oma were equally affected by bone loss.
“Men and women with PRL-oma were equally affected by bone loss (, ).”
Quote in the paperNot a substantial claim - Premisecitation
The association between pegvisomant and incident vertebral fractures is lost after adjustment for activity of acromegaly.
“Additionally, the association between pegvisomant and incident VFs was lost after adjustment for activity of acromegaly ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In acromegaly, vertebral fractures are associated with impaired trabecular and cortical microstructure evaluated by HR-pQCT or bone histomorphometry.
“most of the data were derived from patients with acromegaly in whom VFs were associated with impaired trabecular and cortical microstructure evaluated by either HR-pQCT () or bone histomorphometry ().”
Quote in the paperSubstantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In patients with PRL-oma, treatment with dopamine agonists is accompanied by normalization of serum markers of bone turnover in relationship to normalization of PRL values and restoration of gonadal function.
“In patients with PRL-oma, treatment with dopamine agonists was accompanied by normalization of serum markers of bone turnover in relationship to normalization of PRL values and restoration of gonadal function (, ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In a prospective analysis of GHD, incidence of vertebral fractures is significantly correlated with change in lumbar spine BMD T scores and z scores during the study period.
“When the analysis was performed prospectively, the incidence of VFs was significantly correlated with change in lumbar spine BMD T scores and z scores during the study period ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Biochemical control of acromegaly can be improved by increasing the SRL dose and frequency over conventional regimens.
“the biochemical control of acromegaly can be improved by increasing the SRL dose (, ) and frequency () over the conventional regimens.”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In Cushing's disease, when BMD values are in the osteoporosis range, the prevalence of vertebral fractures is higher.
“when BMD values were in the range of osteoporosis, the prevalence of VFs in CD was shown to be higher (, )”
Quote in the paperSubstantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In PRL-oma, patients with fractures have lower lumbar spine BMD than those without fractures.
“Patients with fractures with PRL-oma showed lower lumbar spine BMD as compared with patients without fractures (, )”
Quote in the paperSubstantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
Even in males, PRL excess may influence fracture risk independent of gonadal status.
“Again, these findings suggest that even in males PRL excess may influence fracture risk independent of gonadal status.”
Quote in the paperSubstantial claim - Premisecitation
Duration of active disease is the most important determinant of vertebral fractures in acromegaly.
“Duration of active disease is the most important determinant of VFs in acromegaly ()”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
Accelerated bone turnover is expected in patients exposed to PRL excess.
“Accelerated bone turnover is expected in patients exposed to PRL excess (), although biochemical data from clinical studies have been variable, with only few studies reporting an increase in serum levels of markers of bone formation and resorption (, ).”
Quote in the paperNot a substantial claim - Premisecitation
Introduction of pegvisomant in the medical therapy of acromegaly, alone or in combination with SRLs, is accompanied by a significant decrease in the incidence of vertebral fractures, in close relationship with biochemical control of acromegaly.
“In a recent longitudinal study, the introduction of pegvisomant in the medical therapy of acromegaly (either alone or in combination with SRLs) was accompanied by a significant decrease in the incidence of VFs, in close relationship with biochemical control of acromegaly ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Some patients with controlled acromegaly still maintain high fracture risk, specifically in the presence of untreated hypogonadism and diabetes mellitus.
“some patients with controlled acromegaly still maintained high fracture risk, specifically in the presence of untreated hypogonadism (, ) and diabetes mellitus ()”
Quote in the paperSubstantial claim0 of 3 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Reduction of BMD was more severe in childhood-onset hyperprolactinemic patients than in those who developed the disease in adulthood.
“In fact, reduction of BMD was more severe in childhood-onset hyperprolactinaemic patients than in those who developed the disease in adulthood (, ).”
Quote in the paperNot a substantial claim - Premisecitation
The risk of vertebral fractures persists high in patients with controlled acromegaly and pre-existing (prevalent) vertebral fractures.
“the risk of VFs persisted high in patients with controlled acromegaly and pre-existing (i.e., prevalent) VFs (, ).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
SRLs can induce tumor shrinkage in more than 50% of treated acromegaly patients.
“SRLs can induce tumor shrinkage in .% of treated patients (, )”
Quote in the paperSubstantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
In PRL-oma, trabecular bone was damaged earlier than cortical bone.
“suggesting that trabecular bone was damaged earlier than cortical bone (, , ).”
Quote in the paperNot a substantial claim - Interpretationreasoning
The negative skeletal effects of abnormal glucose metabolism and lack of sex steroids may be overcome by those produced by chronically increased GH and IGF-I levels.
“suggesting that the negative skeletal effects of abnormal glucose metabolism and lack of sex steroids may be overcome by those produced by chronically increased GH and IGF-I levels.”
Quote in the paperSubstantial claim - Premisecitation
The prevalence of osteoporosis as assessed by DXA in Cushing disease has been reported to be 28% to 50%, in close relationship with activity of disease as assessed by measurement of urinary cortisol values.
“The prevalence of osteoporosis as assessed by DXA has been reported to be % to % (-), in close relationship with activity of disease as assessed by measurement of urinary cortisol values (, ).”
Quote in the paperNot a substantial claim - Premisecitation
The mean spinal bone density in hyperprolactinemic amenorrheic women was significantly lower than that in eumenorrheic hyperprolactinemic women.
“The mean spinal bone density in the hyperprolactinemic amenorrheic women was significantly lower than that in eumenorrheic hyperprolactinemic women ().”
Quote in the paperSubstantial claim - Interpretationreasoning
In acromegaly, bone quality is impaired as an effect of GH hypersecretion.
“supporting the concept that bone quality is impaired as an effect of GH hypersecretion”
Quote in the paperSubstantial claim - Premisecitation
In Cushing's disease, vertebral and nonvertebral fractures are not associated with trabecular and cortical bone microstructure as measured by HR-pQCT.
“vertebral and nonvertebral fractures in CD were not associated with trabecular and cortical bone microstructure as measured by HR-pQCT ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
In acromegaly, vertebral fractures are always a hallmark of skeletal fragility.
“confirming that in acromegaly, such as in other forms of osteoporosis (, ), VFs are always a hallmark of skeletal fragility.”
Quote in the paperSubstantial claim - Interpretationcitation
Repeated measurements of BMD may provide some information about ongoing risk of vertebral fractures.
“repeated measurements of BMD may provide some information about the ongoing risk of VFs.”
Quote in the paperSubstantial claim - Interpretationreasoning
The underlying pituitary disease may alter the effects of rhGH on bone mass.
“The underlying pituitary disease may alter the effects of rhGH on bone mass.”
Quote in the paperSubstantial claim - Premisecitation
Vestergaard et al. showed a 14% decrease of annual rate of clinical fractures after diagnosis of PRL-oma.
“Vestergaard et al. () showed a % decrease of annual rate of clinical fractures after diagnosis of PRL-oma, suggesting a positive impact of treatment on fracture risk.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
The effect of rhGH on biochemical markers of bone turnover is dose-dependent.
“The effect of rhGH on biochemical markers of bone turnover is dosedependent (, , , ) but not influenced by the modality of administration (i.e., continuous vs daily administration, and daily vs administration three times a week) (, ).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, , , )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In prospective and retrospective studies of 10 to 15 years, femoral neck BMD peaked at 5 to 7 years and returned to baseline at 10 to 15 years.
“In prospective and retrospective studies of to years in duration, lumbar spine BMD continued to increase for up to years but subsequently plateaued (, , ), whereas femoral neck BMD peaked at to years and returned to baseline at to years (, ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In a meta-analysis including 31 studies with 1340 patients (902 treated for >12 months), Barake et al. found a significant increase in lumbar spine and femoral neck BMD when treatment was >12 months (18 to 180 months).
“In a recent meta-analysis including studies with patients ( treated for .months), Barake et al. () found a significant increase in lumbar spine and femoral neck BMD when treatment was .months ( to months).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
The earlier recovery of BMD after cure of CD in children compared with adults likely reflects rapid growth and increased bone turnover in the first decades of life.
“The recovery of BMD after the cure of CD seems to occur earlier in children as compared with adults, likely reflecting both the rapid growth and the increase of bone turnover in the first decades of life (, ).”
Quote in the paperSubstantial claim - Premisecitation
rhGH causes an increase in serum and urinary calcium after 3 to 6 months.
“rhGH causes an increase in serum and urinary calcium after to months, an effect caused by calcium mobilization from the skeleton, an increase in intestinal calcium absorption, and in the renal reabsorption of calcium due to increased sensitivity to PTH (-).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (-)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
Underlying genetic differences may play a role in fracture risk of GHD patients.
“Underlying genetic differences may play a role in fracture risk of GHD patients.”
Quote in the paperNot a substantial claim - Premisecitation
In PRL-oma, improvement of BMD is associated more with recovery from hypogonadism than with suppression of PRL levels.
“In general, the improvement of BMD was associated with the recovery from hypogonadism, more than to the suppression of PRL levels (-, , , , ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (-, , , , )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisereasoning
The high incidence of bone-related events makes clinical trials of fracture preventive strategies possible in pituitary disease populations.
“Even considering the relative rarity of pituitary diseases, the high incidence of bone-related events makes such studies possible in those populations, despite the need for multicenter trials with long follow-up.”
Quote in the paperSubstantial claim - Interpretationreasoning
Changes in bone turnover after correction of hypercortisolism are expected to be associated with an increase in BMD.
“These changes in bone turnover are expected to be associated with an increase in BMD, although the densitometric outcomes after treatment of hypercortisolism were shown to be variable, with some patients recovering normal BMD (, ) and others showing persistently abnormal BMD for several years after the cure of CD (, -).”
Quote in the paperSubstantial claim - Study design and conductcitation
The study design of Holmer et al. limited the possibility of separately evaluating the effects of untreated and treated GHD on fracture incidence, because the person-years risk before starting rhGH therapy was too low for a reliable interpretation of GHD-specific fracture risk.
“The study design limited the possibility of separately evaluating the effects of untreated and treated GHD on fracture incidence, because the person-years risk before starting rhGH therapy was too low for a reliable interpretation of GHD-specific fracture risk.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [441] Holmer, 2007, Fracture incidence in GH-deficient patients on complete hormone replacement including GH, J Bone Miner Res source
- Interpretationreasoning
Antiresorptive agents, specifically alendronate, may be used to prevent bone loss during the first months of rhGH therapy in GHD patients.
“These findings suggest that antiresorptive agents, specifically alendronate, may be used to prevent bone loss during the first months of rhGH therapy in GHD patients.”
Quote in the paperSubstantial claim - Premisecitation
Persistently pathological BMD is reported in children several years after cure of CD.
“However, persistently pathological BMD was reported in children several years after cure of CD (, ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
No studies have been performed so far to test the efficacy and safety of antiosteoporotic drugs in acromegaly.
“Despite the growing body of knowledge about bone fragility in acromegaly, no studies have been performed so far to test the efficacy and safety of antiosteoporotic drugs in this clinical setting.”
Quote in the paperNot a substantial claim - Interpretationreasoning
The heterogeneity in glucocorticoid replacement is increased by the absence of reliable biochemical or clinical markers of adequacy of glucocorticoid replacement.
“This is increased by the absence of reliable biochemical or clinical markers of adequacy of glucocorticoid replacement.”
Quote in the paperNot a substantial claim - Interpretationcitation
Fat tissue has a role in the pathophysiology of bone recovery after remission of CD.
“Interestingly, improvement in lumbar spine BMD after the cure of hypercortisolism was predicted by a decrease in body mass index during the follow-up period (), suggesting a role for fat tissue in the pathophysiology of bone recovery after remission of CD ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
After 6 years of follow-up, risk of VFs was sevenfold higher in untreated as compared with treated GHD.
“After 6 years of follow-up, risk of VFs was sevenfold higher in untreated as compared with treated GHD.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [450] Mazziotti, 2016, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency, Endocrine source
- Interpretationreasoning
Monitoring of skeletal health in pituitary diseases cannot be evidence based.
“Because no specific guidelines have been so far published on this topic, the monitoring of skeletal health in pituitary diseases cannot be evidence based.”
Quote in the paperSubstantial claim - Premisecitation
When long-acting glucocorticoids are used, one daily dose of approximately 5 mg prednisone and 0.5 mg dexamethasone is sufficient to replace cortisol insufficiency.
“When long-acting glucocorticoids are used, one daily dose of ~ mg of prednisone and . mg of dexamethasone is sufficient to replace cortisol insufficiency (, ).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisenone given
At these doses, L-T4 may cause skeletal fragility, especially when GHD is replaced.
“However at these doses, L-T may cause skeletal fragility, especially when GHD is replaced”
Quote in the paperSubstantial claim - Premisecitation
Patients with hypopituitarism under treatment with rhGH and estrogens may need higher glucocorticoid dose compared with patients in whom GHD and hypogonadism are not replaced, owing to inhibitory effects of GH on peripheral activation of cortisone in cortisol and decrease of cortisol bioavailability induced by estrogens.
“Patients with hypopituitarism under treatment with rhGH and estrogens may need higher glucocorticoid dose as compared with patients in whom GHD and hypogonadism are not replaced, owing to the inhibitory effects of GH on peripheral activation of cortisone in cortisol () and the decrease of cortisol bioavailability induced by estrogens ().”
Quote in the paperSubstantial claim0 of 2 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationown data
Long-term use of rhGH does not preclude a beneficial effect of antiresorptive agents in GHD patients with osteoporosis.
“Moreover, there is also evidence that the long-term use of rhGH does not preclude a beneficial effect of antiresorptive agents in GHD patients with osteoporosis.”
Quote in the paperSubstantial claim - Premisecitation
The effect of rhGH on biochemical markers of bone turnover is not influenced by modality of administration (continuous vs daily, daily vs three times a week).
“The effect of rhGH on biochemical markers of bone turnover is dosedependent (, , , ) but not influenced by the modality of administration (i.e., continuous vs daily administration, and daily vs administration three times a week) (, ).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Randomized placebo-controlled trials of 18 to 24 months showed mixed results with either improvements or no effects on lumbar spine BMD.
“Randomized placebo-controlled trials of to months showed mixed results with either improvements or no effects on lumbar spine BMD (, ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Longer prospective and nonrandomized studies reported more favorable effects of rhGH therapy on BMD.
“Longer prospective and nonrandomized studies reported more favorable effects of rhGH therapy on BMD (, , ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, , )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Patients with previous fractures are predisposed to develop new fractures after treatment of CD.
“Of note, patients with previous fractures were predisposed to develop new fractures after treatment of CD (), confirming that fractures are a hallmark of skeletal fragility in CD such as observed in other pituitary diseases (, ).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
In prospective and retrospective studies of 10 to 15 years, lumbar spine BMD continued to increase for up to 10 years but subsequently plateaued.
“In prospective and retrospective studies of to years in duration, lumbar spine BMD continued to increase for up to years but subsequently plateaued (, , ), whereas femoral neck BMD peaked at to years and returned to baseline at to years (, ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, , )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Male patients under treatment of PRL-oma show higher prevalence of vertebral fractures compared with age-matched control subjects.
“In fact, male patients under treatment of PRL-oma showed still higher prevalence of VFs as compared with age-matched control subjects ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
The early effects of rhGH on bone turnover may explain why randomized placebo controlled trials of less than a year in duration showed either no significant change in BMD or some decline.
“The early effects of rhGH on bone turnover may explain why randomized placebo controlled trials of less than a year in duration showed either no significant change in BMD or some decline (, , , , , , -).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, , , , , , -)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
Early treatment of CD may have a favorable impact on fracture risk.
“The close association between fragility fractures and severity of hypercortisolism () and duration of disease () suggests that an early treatment of CD may have a favorable impact on fracture risk ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Combining studies that evaluated radiological vertebral fractures, treatment with dopamine agonist is accompanied by a significant decrease in fracture risk (OR, 0.25; 95% CI, 0.11 to 0.59).
“Combining the studies that evaluated radiological VFs, treatment with dopamine agonist was accompanied by a significant decrease in fracture risk (OR, .; % CI, . to .) ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
rhGH replacement therapy may not fully restore bone health in GHD patients previously exposed to GH excess, especially when treatment of GHD is started late after diagnosis of disease and patients had already developed fractures before replacement therapy.
“This finding suggests that rhGH replacement therapy may not fully restore bone health in GHD patients previously exposed to GH excess, especially when treatment of GHD is started late after diagnosis of disease and patients had already developed fractures before replacement therapy.”
Quote in the paperSubstantial claim - Premisenone given
No specific guidelines have been published on monitoring skeletal health in pituitary diseases.
“Because no specific guidelines have been so far published on this topic, the monitoring of skeletal health in pituitary diseases cannot be evidence based.”
Quote in the paperSubstantial claim - Interpretationcitation
The increase in DKK-1 in response to rhGH is consistent with the concept that bone formation is blunted during the first months of treatment.
“Interestingly, a recent study reported an increase in circulating and cortical bone matrix protein levels of the Wnt signaling antagonist DKK- in response to to months of treatment with rhGH, consistent with the concept that bone formation is blunted during the first months of treatment ().”
Quote in the paperSubstantial claim - Premisecitation
A recent study reported an increase in circulating and cortical bone matrix protein levels of the Wnt signaling antagonist DKK-1 in response to 9 to 12 months of treatment with rhGH.
“Interestingly, a recent study reported an increase in circulating and cortical bone matrix protein levels of the Wnt signaling antagonist DKK- in response to to months of treatment with rhGH, consistent with the concept that bone formation is blunted during the first months of treatment ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Effects of dopamine agonists on fracture risk in PRL-oma are largely unknown because only three cross-sectional studies have investigated fracture prevalence in relation to PRL-oma treatment.
“The effects of dopamine agonists on fracture risk are largely unknown, because only three crosssectional studies have investigated the prevalence of fractures in relationship to treatment of PRL-oma (, , ) (Table ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, , )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Early actions of rhGH on skeletal tissue induce activation of multiple bone remodeling units with consequent expansion of remodeling space and transient removal of bone during resorption before new bone is formed.
“The early actions of rhGH on skeletal tissue induce activation of multiple bone remodeling units with consequent expansion of remodeling space and transient removal of bone during resorption before new bone is formed (, ).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
The 14% decrease in annual rate of clinical fractures after PRL-oma diagnosis suggests a positive impact of treatment on fracture risk.
“Vestergaard et al. () showed a % decrease of annual rate of clinical fractures after diagnosis of PRL-oma, suggesting a positive impact of treatment on fracture risk.”
Quote in the paperSubstantial claim - Premisecitation
Improvement in lumbar spine BMD after cure of hypercortisolism is predicted by a decrease in body mass index during follow-up.
“Interestingly, improvement in lumbar spine BMD after the cure of hypercortisolism was predicted by a decrease in body mass index during the follow-up period (), suggesting a role for fat tissue in the pathophysiology of bone recovery after remission of CD ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Replacement therapy with rhGH leads to an increase in bone turnover, as determined by changes in biochemical markers of bone resorption and bone formation.
“Replacement therapy with rhGH leads to an increase in bone turnover, as determined by changes in biochemical markers of bone resorption and bone formation ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
Hydrocortisone has a short half-life of approximately 90 minutes.
“Hydrocortisone has a short half-life (~ minutes) (), and multiple dosing is recommended to try mimicking physiological conditions.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
rhGH may normalize the circadian rhythm of PTH secretion.
“rhGH may normalize the circadian rhythm of PTH secretion ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
There is significant heterogeneity in type, dose, frequency, and timing of glucocorticoid replacement of adrenal insufficiency in real-life clinical practice.
“There is a significant heterogeneity in the type, dose, frequency, and timing of glucocorticoid replacement of adrenal insufficiency in real-life clinical practice ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationcitation
The decrease in BMD at the distal and total radius after cure of hypercortisolism is explained by a possible redistribution of bone minerals from the peripheral to axial skeleton.
“Interestingly, BMD decreased at the distal and total radius in the first to years after the cure of hypercortisolism, and this finding was explained by a possible redistribution of bone minerals from the peripheral to axial skeleton ().”
Quote in the paperNot a substantial claim - Interpretationreasoning
Some patients with cured pituitary disease may maintain high risk of fractures.
“However, some patients with cured pituitary disease may maintain high risk of fractures, providing the rationale to use boneactive drugs in this specific clinical setting”
Quote in the paperSubstantial claim - Premisecitation
The effect of rhGH on bone formation is sustained for prolonged periods of time.
“The effect on bone formation is sustained for prolonged periods of time (, , -).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, , -)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Premisecitation
BMD decreases at the distal and total radius in the first 3 to 4 years after cure of hypercortisolism.
“Interestingly, BMD decreased at the distal and total radius in the first to years after the cure of hypercortisolism, and this finding was explained by a possible redistribution of bone minerals from the peripheral to axial skeleton ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Interpretationreasoning
Biochemical control of acromegaly, PRL-oma, and CD is associated with a significant decrease in risk of fractures, especially when effective treatment is undertaken early after diagnosis.
“In summary, the biochemical control of acromegaly, PRL-oma, and CD was shown to be associated with a significant decrease in the risk of fractures, especially when an effective treatment was undertaken early after diagnosis of disease.”
Quote in the paperSubstantial claim - Premisecitation
Recovery of BMD after cure of CD seems to occur earlier in children compared with adults.
“The recovery of BMD after the cure of CD seems to occur earlier in children as compared with adults, likely reflecting both the rapid growth and the increase of bone turnover in the first decades of life (, ).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- May combine two claims. 76
- Classified as probably not a substantial claim. 11
- The quote only partly states this claim. 2
May combine two claims.
FindingcitationIn a meta-analysis of 13 studies, acromegaly did not induce a significant change in BMD at the lumbar spine, whereas BMD was increased at the femoral neck and total hip.
“In a meta-analysis performed in studies (, , , , -), acromegaly did not induce a significant change in BMD at the lumbar spine, whereas BMD was increased at the femoral neck and total hip ().”
Quote in the paperSubstantial claimMay combine two claims.
FindingcitationFractures may occur even in the presence of normal or low-normal bone mineral density as measured by dual-energy X-ray absorptiometry, making prediction of fractures difficult.
“fractures may occur even in the presence of normal or lownormal bone mineral density as measured by dual-energy X-ray absorptiometry, making difficult the prediction of fractures in these clinical settings.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [1] Mazziotti, 2015, Pituitary diseases and bone, Endocrinol Metab Clin North Am source
May combine two claims.
FindingcitationBeneficial effects of alendronate on BMD were accompanied by a decrease in VF incidence, although the study was not powered for this endpoint.
“The beneficial effects of alendronate on BMD were accompanied by a decrease in VF incidence, although the study was not powered for this endpoint.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [612] Biermasz, 2004, Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study, Clin Endocrinol (Oxf) source
May combine two claims.
FindingcitationIn GHD patients treated with rhGH, pamidronate attenuated the increase in bone turnover and prevented the decline in BMD in the first months.
“The bisphosphonate, administered up-front in six GHD patients treated with rhGH, attenuated the increase in bone turnover and prevented the decline in BMD eventually observed in the first months of GH substitutution.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [609] Valk, 1995, Combined treatment of growth hormone and the bisphosphonate pamidronate, versus treatment with GH alone, in GH-deficient adults: the effects on renal phosphate handling, bone turnover and bone mineral mass, Clin Endocrinol (Oxf) source
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Findingnone givenReduced BMD is not so frequent in patients with acromegaly.
“particularly in the presence of reduced BMD, a finding that is not so frequent in patients with acromegaly.”
Quote in the paperNot a substantial claimMay combine two claims.
Study design and conductcitationDXA measurement of BMD in acromegaly could be influenced by the bone enlargement caused by GH excess, although the effects on bone mineral content seem to overcome those on bone area.
“Moreover, DXA measurement of BMD in acromegaly could be influenced by the bone enlargement caused by GH excess (), although the effects on bone mineral content seem to overcome those on bone area ().”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenHyperfunctioning pituitary diseases are caused by pituitary adenomas.
“Hyperfunctioning pituitary diseases are caused by pituitary adenomas.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
InterpretationreasoningIn a proposed model, a prevalent role of TSH in driving fracture risk may be hypothesized in the presence of normal thyroid hormone levels, and a less relevant role for TSH may be suggested when thyroid hormones rise above the normal levels.
“In this model a prevalent role of TSH in driving fracture risk may be hypothesized in the presence of normal thyroid hormone levels.A less relevant role for TSH may be suggested when thyroid hormones rise above the normal levels.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationAt the femoral neck, volumetric BMD, bone volume fraction, and Tb.N are also strikingly increased in FSH haploinsufficient mice.
“At the femoral neck, volumetric BMD, bone volume fraction, and Tb.N were also strikingly increased.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [198] Sun, 2006, FSH directly regulates bone mass, Cell source
May combine two claims.
Study design and conductcitationDXA does not distinguish between cortical and trabecular bone, and densitometric results are greatly influenced by the variable distribution of these two compartments in the different skeletal sites.
“DXA does not distinguish between cortical and trabecular bone, and densitometric results are greatly influenced by the variable distribution of these two compartments in the different skeletal sites ().”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningWhen PRL values are very high, bone resorption is further stimulated, whereas bone formation is suppressed with consequent impairment of trabecular bone microstructure.
“When PRL values are very high, bone resorption is further stimulated, whereas bone formation is suppressed with consequent impairment of trabecular bone microstructure.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationThe hypercalciuria observed in acromegaly patients is classically linked to increased intestinal calcium absorption driven by calcitriol, as well as to the increased bone turnover induced by GH excess.
“The hypercalciuria observed in acromegaly patients is classically linked to increased intestinal calcium absorption driven by calcitriol, as well as to the increased bone turnover induced by GH excess ().”
Quote in the paperNot a substantial claimMay combine two claims.
PremisereasoningThese effects were independent of thyroid hormones because the women did not have a thyroid gland, and replacement therapy with L-thyroxine was stable during the study period.
“Of note, these effects were independent of thyroid hormones because the women did not have a thyroid gland, and replacement therapy with L-thy- roxine was stable during the study period.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [257] Mazziotti, 2005, Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma, J Bone Miner Res source
May combine two claims.
InterpretationreasoningPRL exerts direct actions on bone remodeling with effects dependent on circulating hormone values and influenced by effects of sex hormones and calcium supply.
“In summary, PRL exerts direct actions on bone remodeling with effects that were shown to be dependent on the circulating hormone values and influenced by the effects of sex hormones and calcium supply.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationPathologically high GH and IGF-I levels exert a deleterious effect on trabecular microarchitecture, whereas cortical bone density tends to be increased as an effect of GH on periostal ossification.
“In fact, pathologically high GH and IGF-I levels exert a deleterious effect on trabecular microarchitecture, whereas cortical bone density tends to be increased as an effect of GH on periostal ossification ().”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationPatients with active acromegaly frequently have phosphate and calcium abnormalities, such as mild hyperphosphatemia, a tendency toward increased plasma calcium levels, and hypercalciuria independently of PTH.
“Patients with active acromegaly frequently have phosphate and calcium abnormalities, such as mild hyperphosphatemia, a tendency toward increased plasma calcium levels, and hypercalciuria independently of PTH (, ).”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningWhen PRL values increase in the range of mild hyperprolactinemia, bone remodeling is further stimulated, with bone resorption increasing more than bone formation.
“When PRL values increase in the range of mild hyperprolactinemia, bone remodeling is further stimulated, with bone resorption increasing more than bone formation.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationVertebral fractures developed more frequently at the thoracic spine and were most commonly anterior wedge fractures.
“Interestingly, VFs developed more frequently at the thoracic spine and they were most commonly anterior wedge fractures (), possibly contributing to kyphosis of patients with acromegaly, a feature clearly present in the first patients reported by Pierre-Marie ().”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationBonadonna et al. identified for the first time vertebral fractures in approximately 50% of postmenopausal women with acromegaly, although densitometric osteoporosis was present in less than 30% of the entire population.
“Bonadonna et al. () identified for the first time VFs in ~% of postmenopausal women with acromegaly, although densitometric osteoporosis was present in ,% of the entire population.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationIncident vertebral fractures developed in 42% of patients with acromegaly during a 3-year follow-up, in close relationship with baseline disease status and duration of active disease.
“Incident VFs developed in % of patients with acromegaly during a -year follow-up, in close relationship with baseline disease status (i.e., higher incidence in patients with active acromegaly) and duration of active disease.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn another study performed in patients with long-standing controlled acromegaly, deletion of exon 3 of GHR was associated with higher prevalence of colonic polyps, dolichocolon, and osteoarthritis, without any significant impact of GHR polymorphism on BMD and vertebral and nonvertebral fractures.
“In another study performed in patients with long-standing controlled acromegaly, deletion of exon- of GHR was associated with higher prevalence of colonic polyps, dolichocolon, and osteoarthritis, without any significant impact of GHR polymorphism on BMD and vertebral and nonvertebral fractures ().”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationElevated plasma phosphate concentrations are related both to increased calcitriol-stimulated dietary phosphate absorption and to a direct antiphosphaturic action of IGF-I in the proximal renal tubule.
“The elevated plasma phosphate concentrations are related both to increased calcitriol-stimulated dietary phosphate absorption and to a direct antiphosphaturic action of IGF-I in the proximal renal tubule, whereas it is uncertain whether hyperphosphatemia may correlate with high bone turnover (, ).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
InterpretationreasoningThe increase of OPG may realize a feed-forward loop inhibiting osteoclastogenesis.
“Interestingly, the increase of OPG may realize a feed-forward loop inhibiting osteoclastogenesis.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationThe overall median prevalence of vertebral fractures in acromegaly was calculated to be approximately 40%, with a fracture risk threefold to eightfold higher than in control subjects.
“Other cross-sectional studies confirmed these findings (, , , ), and the overall median prevalence of VFs was calculated to be ~%, with a fracture risk that was threefold to eightfold higher in acromegaly patients as compared with control subjects ().”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationcitationThere is evidence that TSH may directly inhibit osteoclastogenesis and bone resorption, with concomitant increase in bone formation when hormone exposure is intermittent.
“In summary, there is evidence that TSH may directly inhibit osteoclastogenesis and bone resorption, with concomitant increase in bone formation when hormone exposure is intermittent.”
Quote in the paperSubstantial claimMay combine two claims.
Study design and conductreasoningThe cross-sectional studies were not able to define the causal relationship between GH hypersecretion and vertebral fractures and did not provide reliable information on the clinical predictors of fractures in acromegaly.
“The abovementioned cross-sectional studies were not able to define the causal relationship between GH hypersecretion and VFs and did not provide reliable information on the clinical predictors of fractures in this clinical setting.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningThe clinical relevance of FSH's effect on bone in humans is still largely uncertain, because patients with central hypogonadism are at high risk of bone loss notwithstanding low FSH values.
“The clinical relevance of this effect in humans is still largely uncertain, because patients with central hypogonadism are at high risk of bone loss notwithstanding low FSH values”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationcitationMost patients with acromegaly show normal or even increased BMD at various skeletal sites, and osteopenia and osteoporosis are not common features in acromegaly.
“Most patients with acromegaly show normal or even increased BMD at various skeletal sites, and osteopenia and osteoporosis are not common features in acromegaly.”
Quote in the paperSubstantial claimMay combine two claims.
PremisereasoningThere are no clinical studies specifically evaluating the direct effects of PRL at different concentrations, because in most cases the relative contributions of PRL excess and sex steroid deficiency are difficult to discriminate.
“There are no clinical studies specifically evaluating the direct effects of PRL at different concentrations, because in most cases the relative contributions of PRL excess and sex steroid deficiency are difficult to be discriminated.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationPolymorphism of GHR characterized by deletion of exon 3 with consequent higher sensitivity to GH was associated with a higher prevalence of vertebral fractures in patients with acromegaly, with stronger association in females as compared with males.
“Polymorphism of GHR, characterized by deletion of exon- with consequent higher sensitivity to GH, was associated with a higher prevalence of VFs in patients with acromegaly (), with stronger association in females as compared with males ().”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn patients with TSH-oma with persistent hyperthyroidism after neurosurgery, first-generation SRLs can normalize TSH and thyroid hormone levels in more than 90% of patients and reduce tumor size in more than 40% of patients.
“Patients with TSH-oma with persistent hyperthyroidism after neurosurgery can be treated with firstgeneration SRLs that can normalize TSH and thyroid hormone levels in .% of patients and reduce tumor size in .% of patients ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationAcromegaly was shown to affect cortical bone in terms of increased porosity and impaired cortical strength.
“Besides the abnormalities in trabecular microstructure, acromegaly was shown to also affect cortical bone in terms of increased porosity (, , ) and impaired cortical strength ().”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn untreated GHD, vertebral fractures are associated with BMD, with highest fracture risk in patients with T score below -2.0 SD.
“In patients with untreated GHD, VFs were associated with BMD, because the highest risk to develop fractures was found in patients with a T score below 2. SD ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationIn clinical trials, octreotide LAR and lanreotide autogel normalize GH and IGF-I in half to two-thirds of patients, whereas success rate is lower in surveys involving nonselected cohorts.
“In clinical trials, octreotide LAR and lanreotide autogel have been reported to normalize GH and IGF-I in half to two-thirds of patients (), whereas success rate was shown to be lower in surveys involving nonselected cohorts of patients ().”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationWhen performed by experienced neurosurgeons, remission of pituitary hyperfunction can be achieved in 80% to 90% of patients with microadenomas and 40% to 70% of those with macroadenomas, with a 10% to 20% recurrence rate over several years.
“remission of pituitary hyperfunction can be achieved in % to % of patients with microadenomas and % to % of those with macroadenomas, with a % to % of recurrence rate over several years (, ).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
Premiseown dataThe prevalence of vertebral fractures in postmenopausal women with PRL-oma was higher than in control women of comparable age, in close relationship with duration of hyperprolactinemia (OR 1.16; 95% CI 1.04 to 1.30) but not with age of onset of hyperprolactinemia (OR 0.72; 95% CI 0.4 to 3.6).
“Of note, the prevalence of VFs in postmenopausal women was higher as compared with control women of comparable age, in close relationship with the duration of hyperprolactinemia (OR, .; % CI, . to .) but not with the age of onset of hyperprolactinemia (OR, .; % CI, . to .).”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationDopamine agonists are the first-line therapy of PRL-oma because they may normalize PRL values, decrease tumor mass, and improve clinical symptoms in most patients.
“Dopamine agonists are the first-line therapy of PRL-oma because they may normalize PRL values, decrease tumor mass, and improve clinical symptoms in most patients (, ).”
Quote in the paperNot a substantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationreasoningPRL-oma causes high bone turnover osteoporosis, with low BMD occurring in most patients, especially when the disease develops in the first decades of life before the achievement of peak bone mass.
“In summary, PRL-oma causes high bone turnover osteoporosis, with low BMD occurring in most patients, especially when the disease develops in the first decades of life before the achievement of peak bone mass.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
InterpretationreasoningThe higher frequency of incident vertebral fractures with pegvisomant compared with SRLs may reflect different severity of acromegaly in patients treated with the two drugs.
“In fact, such a finding may reflect different severity of acromegaly in patients treated with the two drugs.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationThe annual fracture rate was 1.4% before and 1.2% after diagnosis among patients with PRL-oma, and 0.9% and 1.0%, respectively, among controls.
“The annual fracture rate was .% before and .% after diagnosis among the patients with PRL-oma, and .% and .%, respectively, among their controls ().”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn a study of 78 women with PRL-oma, radiological vertebral fractures were found in 25 women (32.6%), with prevalence higher in postmenopausal women (22 of 40) than in premenopausal women (3 of 38).
“The first study was carried out in women ( were premenopausal and were in the postmenopausal period) who were evaluated for VFs using quantitative morphometry ().Radiological VFs were found in out of these women (.%), with the prevalence being higher in postmenopausal women ( of ) as compared with premenopausal women ( of ).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.
Premisenone givenIn Cushing's original series of 12 patients published in 1932, radiographic osteoporosis was reported in 1 patient, 6 patients were reported to have kyphosis, and 2 were reported to have spontaneous fractures.
“In Cushing's original series of patients published in , radiographic osteoporosis was reported in patient, patients were reported to have kyphosis, and were reported to have spontaneous fractures.”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationHong et al. found a 6% lower trabecular bone score in males and females with acromegaly as compared with control subjects, without any significant difference in BMD.
“Hong et al. () found a % lower TBS in males and females with acromegaly as compared with control subjects, without any significant difference in BMD.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn Cushing's disease, TBS is deteriorated more than BMD, but neither parameter is associated with fractures.
“TBS was shown to be deteriorated more than BMD, but both the parameters were not associated with fractures ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationMonitoring of mifepristone treatment can be difficult because ACTH and cortisol levels increase rather than decrease, and overdosing causing adrenal insufficiency can occur.
“Monitoring of mifepristone treatment can be difficult because ACTH and cortisol levels increase rather than decrease, and overdosing causing adrenal insufficiency can occur ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationreasoningBone turnover is invariably increased in patients with active acromegaly, whereas BMD as measured by DXA is generally slightly decreased or even normal.
“Bone turnover is invariably increased in patients with active acromegaly, whereas BMD as measured by DXA is generally slightly decreased or even normal.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn acromegaly, lumbar BMD does not differ between patients with and without fractures, but meta-analysis heterogeneity was too high to conclude.
“These studies did not show any difference in BMD between the two groups, although the heterogeneity was too high to achieve conclusions in this regard ().”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationCabergoline is more effective in normalizing PRL values, with fewer side effects, compared with bromocriptine.
“Carbergoline was shown to be more effective in normalizing PRL values, with fewer side effects, as compared with bromocriptine ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S1 (asserted).
InterpretationreasoningBone loss in patients with hyperprolactinemia may be synergistically determined by increased PRL levels per se and by concomitant sex hormone deprivation.
“Therefore, it is possible to hypothesize that bone loss in patients with hypeprolactinemia may be synergistically determined by increased PRL levels per se and by the concomitant sex hormone deprivation.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationcitationPatients with PRL-oma are predisposed to develop osteopenia, osteoporosis, and fragility fractures as an effect of hypogonadism induced by PRL excess, as well as direct actions of PRL on bone cells and calcium metabolism.
“Patients with PRL-oma are predisposed to develop osteopenia, osteoporosis, and fragility fractures as an effect of hypogonadism induced by PRL excess, as well as an effect of direct actions of PRL on bone cells and calcium metabolism ().”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationIn acromegaly, incident vertebral fractures occur more frequently during treatment with pegvisomant compared with SRLs.
“In a prospective study, incident VFs were reported to occur more frequently during treatment with pegvisomant as compared with SRLs ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationCurrently available adrenal steroidogenesis inhibitors have variable efficacy and significant side effects, but they are not approved by the US Food and Drug Administration for Cushing's disease.
“Currently available adrenal steroidogenesis inhibitors, including ketoconazole, metyrapone, etomidate, and mitotane, have variable efficacy and significant side effects, but they are not approved by the US Food and Drug Administration for CD ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationSkeletal fragility is a frequent complication of endogenous hypercortisolism, and fragility fractures may be the presenting clinical feature of disease.
“Indeed, skeletal fragility is a frequent complication of endogenous hypercortisolism, and fragility fractures may be the presenting clinical feature of disease (, ).”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningThere is consistent evidence that GH excess causes deterioration of bone microstructure leading to high risk of vertebral fractures in close relationship with duration of active acromegaly.
“In summary, there is consistent evidence that GH excess causes deterioration of bone microstructure leading to high risk of VFs in close relationship with duration of active acromegaly.”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningThe pathogenesis of PRL-oma-induced bone loss is multifactorial, because both direct and indirect (hypogonadism) skeletal effects of hyperprolactinemia may be involved.
“The pathogenesis of PRL-oma-induced bone loss is multifactorial, because both direct and indirect (hypogonadism) skeletal effects of hyperprolactinemia may be involved.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn untreated GHD, all patients with osteoporosis and all but one with osteopenia had vertebral fractures.
“all untreated patients with osteoporosis (T score # 2. SD) and all but one patient with osteopenia (T score between 2. and 2. SD) had VFs.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationBone loss in Cushing disease was more pronounced at the lumbar spine and femoral neck, consistent with the view that trabecular bone is a principal target for the detrimental actions of glucocorticoid excess in the skeleton.
“The bone loss was more pronounced at the lumbar spine and femoral neck, consistent with the view that trabecular bone is a principal target for the detrimental actions of glucocorticoid excess in the skeleton (, , -).”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationNeurosurgery is the first-line therapy for Cushing's disease, acromegaly, and TSH-oma.
“Neurosurgery is the first-line therapy of CD (), acromegaly (, ), and TSH-oma ().”
Quote in the paperNot a substantial claim0 of 3 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
The quote only partly states this claim.
InterpretationreasoningIn such patients, evaluation of bone microstructure may provide reliable information on the risk of fractures.
“the evaluation of bone microstructure may provide some reliable information on the risk of fractures”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationPegvisomant is a pegylated recombinant GH analog designed to interfere with dimerization of GHR and thus blocks production of IGF-I without any direct effect on pituitary tumor.
“Pegvisomant is a pegylated recombinant GH analog designed to interfere with dimerization of GHR and thus blocks production of IGF-I () without any direct effect on pituitary tumor.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationIn acromegaly, vertebral fractures occur even in patients with normal BMD, especially when acromegaly is active.
“VFs occurred even in patients with normal BMD, especially when acromegaly was active ()”
Quote in the paperSubstantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationIn an uncontrolled study of 48 naive patients with active acromegaly, trabecular bone score was found to be partially degraded, whereas BMD z scores in most compartments did not differ from 0.
“In another uncontrolled study performed in naive patients with active acromegaly, TBS was found to be partially degraded according to the definition by the manufacturer, whereas BMD z scores in most compartments did not differ from ().”
Quote in the paperSubstantial claimMay combine two claims. The quote only partly states this claim.
PremisecitationThe prevalence of vertebral fractures was not significantly different between eugonadal and hypogonadal patients with PRL-oma, and no significant difference in serum testosterone values was found between males with or without fractures.
“Interestingly, the prevalence of VFs was not significantly different between eugonadal and”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn a second cross-sectional study, radiological vertebral fractures were found in 37.5% of male patients with PRL-oma, with prevalence about fivefold higher as compared with control subjects.
“In the second crosssectional study, radiological VFs were found in .% of male patients with PRL-oma, with the prevalence being about fivefold higher as compared with control subjects ().”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationIn patients with pituitary diseases, experience with fracture risk assessment algorithms is limited, with inconclusive results concerning their reliability in predicting fractures.
“In patients with pituitary diseases, the experience with these algorithms is limited (, ), with inconclusive results concerning the reliability in predicting fractures in this clinical setting.”
Quote in the paperSubstantial claim0 of 2 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationBiochemical control of acromegaly is accompanied by variable changes in BMD and persistently abnormal bone structure.
“This biochemical effect was accompanied by variable changes in BMD (, , , , , , , ) and with persistently abnormal bone structure (, ).”
Quote in the paperSubstantial claim0 of 3 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationMifepristone is a glucocorticoid receptor antagonist that improves glucose tolerance, body weight, and quality of life in Cushing's disease.
“Mifepristone is a glucocorticoid receptor antagonist that improves glucose tolerance, body weight, and quality of life in CD ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationEighty percent of male patients with PRL-oma were found to have densitometric diagnosis of either osteopenia or osteoporosis at the lumbar spine, whereas only 30% showed a low BMD at the femoral neck.
“Eighty percent of male patients with PRL-oma were found to have densitometric diagnosis of either osteopenia or osteoporosis at the lumbar spine, whereas only a minority of them (%) showed a low BMD at the femoral neck, suggesting that trabecular bone was damaged earlier than cortical bone (, , ).”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn some studies, BMD was correlated with PRL levels, biochemical markers of bone turnover, and duration of disease, but not with serum testosterone values in males or estradiol values and coexistent amenorrhea in women.
“In some studies, BMD was correlated with PRL levels, biochemical markers of bone turnover, and duration of disease, but not with serum testosterone values in males () or estradiol values and coexistent amenorrhea in women ().”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationThe increase in BMD after cure of CD is larger and occurs earlier at the lumbar spine compared with the total hip.
“The increase in BMD was larger and occurred earlier at the lumbar spine as compared with the total hip (, ).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationcitationChanges in BMD after cure of CD are time-dependent and skeletal site specific.
“Changes in BMD after the cure of CD are time-dependent and skeletal site specific.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationIn a retrospective analysis, no incident clinical fractures were registered during a period of 4 years after cure of hypercortisolism, although the number of patients with long-term follow-up was too low to draw definitive conclusions.
“In a retrospective analysis, no incident clinical fractures were registered during a period of years after the cure of hypercortisolism, although the number of patients with long-term follow-up was too low to draw definitive conclusions ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationVestergaard et al. reported a significant decrease in risk of clinical fractures early after diagnosis of CD, although it was not specified whether this outcome was related to correction of hypercortisolism or to other treatments.
“In fact, Vestergaard et al. () reported a significant decrease in risk of clinical fractures early after diagnosis of CD (Table ), although it was not specified whether this outcome was related to correction of hypercortisolism or to other treatments (e.g., sex steroids or vitamin D) potentially impacting fracture risk in this clinical setting (-).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationA high prevalence of vertebral fractures is reported in patients with long-standing cured CD, although the cross-sectional design did not allow definition of timing of fracture development and progression in relationship to outcome of hypercortisolism.
“Alternatively, a high prevalence of VFs was reported in patients with long-standing cured CD (Table ), although the cross-sectional design did not allow definition of the timing of fracture development and progression in relationship to the outcome of hypercortisolism ().”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationcitationFractures are a hallmark of skeletal fragility in CD, as observed in other pituitary diseases.
“Of note, patients with previous fractures were predisposed to develop new fractures after treatment of CD (), confirming that fractures are a hallmark of skeletal fragility in CD such as observed in other pituitary diseases (, ).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationDensitometric outcomes after treatment of hypercortisolism are variable: some patients recover normal BMD and others show persistently abnormal BMD for several years after cure of CD.
“These changes in bone turnover are expected to be associated with an increase in BMD, although the densitometric outcomes after treatment of hypercortisolism were shown to be variable, with some patients recovering normal BMD (, ) and others showing persistently abnormal BMD for several years after the cure of CD (, -).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites (, -)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).
Premisenone givenHR-pQCT is apparently the gold standard for assessing bone quality and microstructure.
“In fact, although HR-pQCT is apparently the gold standard in the arena, its costs make its availability for routine evaluation unrealistic.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Premisenone givenThe role of bone-active drugs in the treatment of bone complications in pituitary diseases is almost unexplored.
“Another so far almost unexplored territory is the role of bone-active drugs in the treatment of bone complications in pituitary diseases.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationrhGH is antiphosphaturic and increases intestinal absorption of phosphate, leading to an increase in serum phosphate levels.
“rhGH is antiphosphaturic and increases the intestinal absorption of phosphate, leading to an increase in serum phosphate levels (-).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (-)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationThere is a close association between fragility fractures and severity of hypercortisolism and duration of disease.
“The close association between fragility fractures and severity of hypercortisolism () and duration of disease () suggests that an early treatment of CD may have a favorable impact on fracture risk ().”
Quote in the paperSubstantial claim0 of 2 sources checked- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- cites ()
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Classified as probably not a substantial claim.
Premisenone givenCosts of HR-pQCT make its availability for routine evaluation unrealistic.
“In fact, although HR-pQCT is apparently the gold standard in the arena, its costs make its availability for routine evaluation unrealistic.”
Quote in the paperSubstantial claimMay combine two claims.
PremisecitationThe effect of rhGH on bone remodeling is biphasic: rhGH causes a maximal effect on bone resorption after 3 months and on bone formation after 6 months.
“The effect of rhGH on bone remodeling is biphasic; that is, rhGH causes a maximal effect on bone resorption after months and on bone formation after months.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, , -)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
InterpretationcitationThe increase in serum and urinary calcium caused by rhGH is due to calcium mobilization from the skeleton, increased intestinal calcium absorption, and increased renal reabsorption of calcium due to increased sensitivity to PTH.
“rhGH causes an increase in serum and urinary calcium after to months, an effect caused by calcium mobilization from the skeleton, an increase in intestinal calcium absorption, and in the renal reabsorption of calcium due to increased sensitivity to PTH (-).”
Quote in the paperNot a substantial claimMay combine two claims.
PremisecitationL-T4 doses in central hypothyroidism average 1.6 mg/kg/d, based on evidence that this dose is associated with improvement in several clinical endpoints of central hypothyroidism.
“L-T doses in central hypothyroidism average . mg/kg/d, based on the evidence that this hormone dose was associated with an improvement in several clinical endpoints of central hypothyroidism (-).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (-)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationIn patients with PRL-oma, BMD values only partially improve during treatment and remain lower than in normal control subjects.
“BMD values, however, only partially improved during treatment, remaining still lower as compared with normal control subjects (, -, , -).”
Quote in the paperSubstantial claim0 of 1 sources checked- cites (, -, , -)
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
May combine two claims.
PremisecitationCorrection of hypercortisolism is accompanied by a marked increase in osteocalcin levels and moderate increase or even decrease in NTX levels.
“Correction of hypercortisolism was accompanied by a marked increase in osteocalcin levels and moderate increase or even decrease in NTX levels (, ).”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites (, )
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
The paper relies on this without support.
Skeletal fragility associated with high risk of fractures is a common complication of hypopituitarism, Cushing disease, acromegaly, and hyperprolactinemia.
“Skeletal fragility associated with high risk of fractures is a common complication of several pituitary diseases such as hypopituitarism, Cushing disease, acromegaly, and hyperprolactinemia.”
The paper relies on this without support.
The control groups in the cited studies are appropriate comparators for patients with pituitary disease.
“as compared with control subjects”
The paper relies on this without support.
The fracture definitions used in the cited studies accurately identify fragility fractures.
“radiological VFs were found”
The paper relies on this without support.
Bisphosphonates inhibit bone resorption.
“Bisphosphonates inhibit bone resorption and are the most commonly prescribed drugs for the treatment of osteoporosis.”
The paper relies on this without support.
Bisphosphonates may potentially delay the recovery of bone remodeling after resolution of endogenous hypercortisolism.
“In fact, it should be considered that bisphosphonates may potentially delay the recovery of bone remodeling after resolution of endogenous hypercortisolism.”
The paper relies on this without support.
Pituitary diseases are burdened by relevant osteometabolic derangements.
“Pituitary diseases are burdened by relevant osteometabolic derangements.”
The paper relies on this without support.
For mainly economic reasons, substitution with rhGH has become progressively less popular in our health systems and among endocrinologists.
“For mainly economic reasons the substitution with rhGH has become progressively less popular in our health systems and among endocrinologists.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Four GHD drug studies are called alendronate studies, but one used pamidronate
MinorOf the four GHD studies discussed immediately afterward and listed in Table 5, the Valk study used pamidronate rather than alendronate.
“Four studies evaluated the efficacy of alendronate in hypopituitary patients with GHD (Table ).”
“| Valk et al., 1995 | Prospective | GHD | 6 (50% F) | 0/6 | Pamidronate | 6 | ↑LS BMC in GHD treated with rhGH plus |”
The same PRL model is described as having both unchanged and decreased BMD
MinorThe description of the experimental model first says BMD was not altered, then refers to a decrease in BMD in that model.
“In this experimental model, BMD and bone mineral content were not altered”
“which also explained the decrease in BMD observed in this model.”
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · see citing works
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602 · see citing works
Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*
Jones, J. I. W., & Clemmons, D. R. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-1-3 · Cited by 4,488 · see citing works
Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., & de Crombrugghe, B. (2002) · Cell · doi:10.1016/s0092-8674(01)00622-5 · Cited by 3,608 · see citing works
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · see citing works
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C. C., Rizzoli, R., & Reginster, J. (2012) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,954 · see citing works
Prolactin: structure, function, and regulation of secretion
Freeman, M. E., Kanyicska, B., Lerant, A., & Nagy, G. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.4.1523 · Cited by 2,457 · see citing works
Bone Quality — The Material and Structural Basis of Bone Strength and Fragility
Seeman, E., & Delmas, P. D. (2006) · New England Journal of Medicine · doi:10.1056/nejmra053077 · Cited by 2,108 · see citing works
Insulin-like growth factors and their binding proteins: biological actions
Jones, J. I. (1995) · Endocrine Reviews · doi:10.1210/er.16.1.3 · Cited by 2,060 · see citing works
Bôle-Feysot, C., Goffin, V., Edery, M., Binart, N., & Kelly, P. (1998) · Endocrine reviews · doi:10.1210/edrv.19.3.0334 · Cited by 1,973 · see citing works
Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects
Christakos, S., Dhawan, P., Verstuyf, A., Verlinden, L., & Carmeliet, G. (2015) · Physiological Reviews · doi:10.1152/physrev.00014.2015 · Cited by 1,965 · see citing works
Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline
Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1692 · Cited by 1,844 · see citing works
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · see citing works
Schuit, S. C. E., van der Klift, M., Weel, A. E. A. M., de Laet, C. E. D. H., Burger, H., Seeman, E., Hofman, A., Uitterlinden, A. G., van Leeuwen, J. P. T. M., & Pols, H. A. P. (2004) · Bone · doi:10.1016/j.bone.2003.10.001 · Cited by 1,651 · see citing works
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,484 · see citing works
Regulation of bone mass by Wnt signaling
Krishnan, V. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28551 · Cited by 1,407 · see citing works
β-Arrestins and Cell Signaling
DeWire, S. M., Ahn, S., Lefkowitz, R. J., & Shenoy, S. K. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.022405.154749 · Cited by 1,397 · see citing works
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270 · see citing works
Giustina, A., & Veldhuis, J. D. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.6.0353 · Cited by 1,253 · see citing works
Self-citationfor the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212 · see citing works
Canonical WNT Signaling Promotes Osteogenesis by Directly Stimulating Runx2 Gene Expression
Gaur, T., Lengner, C. J., Hovhannisyan, H., Bhat, R. A., Bodine, P. V. N., Komm, B. S., Javed, A., van Wijnen, A. J., Stein, J. L., Stein, G. S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500608200 · Cited by 1,170 · see citing works
Denosumab in men receiving androgen-deprivation therapy for prostate cancer
Smith, M. R., Egerdie, B., Toriz, N. H., Feldman, R., Tammela, T. L. J., Saad, F., Heracek, J., Szwedowski, M., Ke, C., Kupic, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809003 · Cited by 1,140 · see citing works
Glucocorticoid-induced osteoporosis: pathophysiology and therapy
CANALIS, E. M., Mazziotti, G., Giustina, A., & Bilezikian, J. P. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0394-0 · Cited by 1,118 · see citing works
Self-citationThe Insulin-Like Growth Factor-Binding Protein (IGFBP) Superfamily
Hwa, V., Oh, Y., & Rosenfeld, R. G. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0382 · Cited by 1,076 · see citing works
Stone, K. L., Seeley, D. G., Lui, L., Cauley, J. A., Ensrud, K. E., Browner, W. S., Nevitt, M. C., & Cummings, S. R. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.11.1947 · Cited by 1,053 · see citing works
Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047 · see citing works
The Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042 · see citing works
Transcriptional Activators of TGF-β Responses: Smads
Derynck, R., Zhang, Y. E., & Feng, X. (1998) · Cell · doi:10.1016/s0092-8674(00)81696-7 · Cited by 1,035 · see citing works
Diagnosis and Treatment of Pituitary Adenomas
Molitch, M. E. (2017) · JAMA · doi:10.1001/jama.2016.19699 · Cited by 1,016 · see citing works
Bisphosphonates: Mechanisms of Action
Fleisch, H. A. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0325 · Cited by 1,015 · see citing works
Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts
Nakamura, T., Imai, Y., Matsumoto, T., Sato, S., Takeuchi, K., Igarashi, K., Harada, Y., Azuma, Y., Krust, A., Yamamoto, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.025 · Cited by 1,013 · see citing works
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology
Tat, S. K., Marc, P., Théoleyre, S., Heymann, D., & Fortun, Y. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2003.10.005 · Cited by 959 · see citing works
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945 · see citing works
Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis
Saag, K. G., Shane, E., Boonen, S., Marín, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., & Marcus, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071408 · Cited by 914 · see citing works
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Giustina, A., Mazziotti, G., & CANALIS, E. M. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0036 · Cited by 910 · see citing works
Self-citationBianco, P., & Robey, P. G. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10413 · Cited by 908 · see citing works
Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.
Czock, D., Keller, F., Rasche, F. M., & H??ussler, U. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00003 · Cited by 886 · see citing works
Simoni, M., Gromoll, J., & Nieschlag, E. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0320 · Cited by 886 · see citing works
Regulation of osteoblastogenesis and bone mass by Wnt10b
Bennett, C. N., Longo, K. A., Hahn, W. S., Suva, L. J., Lane, T. F., Hankenson, K. D., & MacDougald, O. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408742102 · Cited by 882 · see citing works
Ohlsson, C., Bengtsson, B., Isaksson, O. G. P., Andreassen, T. T., & Slootweg, M. C. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.1.0324 · Cited by 863 · see citing works
Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton
CANALIS, E. M., Economides, A. N., & Gazzerro, E. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0023 · Cited by 861 · see citing works
Estrogens and androgens in skeletal physiology and pathophysiology
Almeida, M., Laurent, M. R., Dubois, V., Claessens, F., O'Brien, C. A., Bouillon, R., Vanderschueren, D., & Manolagas, S. C. (2017) · Physiological Reviews · doi:10.1152/physrev.00033.2015 · Cited by 860 · see citing works
Nevitt, M. C., Ettinger, B., Black, D. M., Stone, K. L., Jamal, S. A., Ensrud, K. E., Segal, M. R., Genant, H. K., & Cummings, S. R. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-10-199805150-00001 · Cited by 841 · see citing works
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J., Abs, R., Bonert, V. S., Bronstein, M. D., Brue, T. C., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 824 · see citing works
Self-citationMatkovic, V, Jelic, T., Wardlaw, G. M., Ilich, J. Z., Goel, P. K., Wright, J. K., Andon, M. B., Smith, K. T., & Heaney, R. P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117034 · Cited by 806 · see citing works
Wnt signaling in osteoblasts and bone diseases
Westendorf, J. J., Kahler, R. A., & Schroeder, T. M. (2004) · Gene · doi:10.1016/j.gene.2004.06.044 · Cited by 805 · see citing works
Zhou, Y., Xu, B. C., Maheshwari, H., He, L., Reed, M. A., Lozykowski, M. G., Okada, S., Cataldo, L. R., Coschigamo, K., Wagner, T. E., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13215 · Cited by 802 · see citing works
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794 · see citing works
Katznelson, L., Finkelstein, J. S., Schoenfeld, D. A., Rosenthal, D. I., Anderson, E. J., & Klibanski, A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.12.8954042 · Cited by 791 · see citing works
Heaney, R., Abrams, S., Dawson-Hughes, B., Looker, A., Marcus, R., Matkovic, V., & Weaver, C. (2000) · Osteoporosis International · doi:10.1007/s001980070020 · Cited by 784 · see citing works
Osteoclast–osteoblast communication
Matsuo, K., & Irie, N. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.027 · Cited by 780 · see citing works
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. А., Burlet, N., Cooper, C. C., Delmas, P. D., Reginster, J., Borgström, F., & Rizzoli, R. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 778 · see citing works
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2003) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771 · see citing works
Guidelines for Acromegaly Management: An Update
Melmed, S. K., Colao, A., Barkan, A. L., Molitch, M. E., Grossman, A. B., Kleinberg, D. L., Clemmons, D. R., Chanson, P., Laws, E. R., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 762 · see citing works
Self-citationOsteoclasts: What Do They Do and How Do They Do It?
Teitelbaum, S. L. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060834 · Cited by 730 · see citing works
FSH Directly Regulates Bone Mass
Sun, L., Peng, Y., Sharrow, A. C., Iqbal, J., Zhang, Z., Papachristou, D. J., Zaidi, S., Zhu, L.-L., Yaroslavskiy, B. B., Zhou, H., et al. (2006) · Cell · doi:10.1016/j.cell.2006.01.051 · Cited by 723 · see citing works
Molecular and cellular mechanisms of the anabolic effect of intermittent PTH
Jilka, R. L. (2007) · Bone · doi:10.1016/j.bone.2007.03.017 · Cited by 722 · see citing works
Hodsman, A. B., Bauer, D. C., Dempster, D. W., Dian, L., Hanley, D. A., Harris, S. T., Kendler, D. L., McClung, M. R., Miller, P. D., Olszynski, W. P., et al. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0006 · Cited by 717 · see citing works
Anabolic Actions of Parathyroid Hormone on Bone*
Dempster, D. W., Cosman, F., Parisien, M. V., Shen, V., & Lindsay, R. (1993) · Endocrine Reviews · doi:10.1210/edrv-14-6-690 · Cited by 717 · see citing works
Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717 · see citing works
Zhang, M., Xuan, S., Bouxsein, M., Stechow, D. V., Akeno, N., Faugere, M.-C., Malluche, H. H., Zhao, G., Rosen, C. J., Efstratiadis, A., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208265200 · Cited by 696 · see citing works
TSH Is a Negative Regulator of Skeletal Remodeling
Abe, E., Marians, R. C., Yu, W., Wu, X.-B., Ando, T., Li, Y., Iqbal, J., Eldeiry, L., Rajendren, G., Blair, H. C., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00771-2 · Cited by 691 · see citing works
Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2017) · Annals of Internal Medicine · doi:10.7326/m15-1361 · Cited by 676 · see citing works
Pistoia, W., van Rietbergen, B., Lochmüller, E., Lill, C. A., Eckstein, F., & Ruegsegger, P. (2002) · Bone · doi:10.1016/s8756-3282(02)00736-6 · Cited by 643 · see citing works
Genant, H. K., Jergas, M. D., Palermo, L., Nevitt, M. C., Valentin, R. S., Black, D. M., & Cummings, S. R. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110716 · Cited by 634 · see citing works
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells
Xian, L., Wu, X., Pang, L., Lou, M., Rosen, C. J., Qiu, T., Crane, J., Frassica, F., Zhang, L., Rodriguez, J. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2793 · Cited by 631 · see citing works
Structure and function of the type 1 insulin-like growth factor receptor
Adams, T. E., Epa, V. C., Garrett, T., & Ward, C. W. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000744 · Cited by 629 · see citing works
A 12-month phase 3 study of pasireotide in Cushing's disease
Colao, A., Petersenn, S., Newell-Price, J., Findling, J. W., Gu, F., Maldonado, M., Schoenherr, U., Dipl.-Biol., Mills, D., Salgado, L. R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105743 · Cited by 628 · see citing works
Park, D., Spencer, J. A., Koh, B. I., Kobayashi, T., Fujisaki, J., Clemens, T. L., Lin, C. P., Kronenberg, H. M., & Scadden, D. T. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.02.003 · Cited by 627 · see citing works
Effects of Testosterone Replacement in Hypogonadal Men1
Snyder, P. J., Peachey, H., Berlin, J. A., Hannoush, P., Haddad, G., Dlewati, A., Santanna, J., Loh, L., Lenrow, D. A., Holmes, J. H., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6731 · Cited by 608 · see citing works
Wu, Z., Bucher, N. L. R., & Farmer, S. R. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.8.4128 · Cited by 605 · see citing works
Godowski, P. J., Leung, D. W., Meacham, L. R., GALGANI, J. P., Hellmiss, R., Keret, R., Rotwein, P. S., Parks, J. S., Laron, Z., & Wood, W. I. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.8083 · Cited by 604 · see citing works
Hu, M. C., Shiizaki, K., Kuro-o, M., & Moe, O. W. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183727 · Cited by 587 · see citing works
Buckley, L. M., Guyatt, G. H., Fink, H. A., Cannon, M. D., Grossman, J., Hansen, K. E., Humphrey, M. B., Lane, N. E., Magrey, M., Miller, M. A., et al. (2017) · Arthritis Care & Research · doi:10.1002/acr.23279 · Cited by 578 · see citing works
Nohe, A., Haßel, S., Ehrlich, M., Neubauer, F. B., Sebald, W., Henis, Y. I., & Knaus, P. I. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m102750200 · Cited by 566 · see citing works
Gnant, M., Pfeiler, G., Dubsky, P. C., Hubalek, M., Greil, R., Jakesz, R., Wette, V., Balić, M., Haslbauer, F., Melbinger‐Zeinitzer, E., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60995-3 · Cited by 562 · see citing works
Long-term effect of testosterone therapy on bone mineral density in hypogonadal men
Behre, H. M., Kliesch, S., Leifke, E., Link, T. M., & Nieschlag, E. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.8.4163 · Cited by 559 · see citing works
Schousboe, J. T., Shepherd, J., Bilezikian, J. P., & Baim, S. (2013) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.08.004 · Cited by 547 · see citing works
CANALIS, E. M., Burch, W. M., & McCarthy, T. L. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113885 · Cited by 546 · see citing works
Khan, A. A., Hanley, D. A., Rizzoli, R., Bollerslev, J., Young, J. E. M., Rejnmark, L., Thakker, R. V., D'AMOUR, P., Paul, T., Uum, S. H. M. V., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3716-2 · Cited by 544 · see citing works
Role of Thyroid Hormones in Skeletal Development and Bone Maintenance
Bassett, J. H. D., & Williams, G. R. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1106 · Cited by 540 · see citing works
Signal transduction by bone morphogenetic proteins
Kawabata, M. (1998) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(97)00036-1 · Cited by 530 · see citing works
Oleksik, A. M., Lips, P. T. A. M., Dawson, A., Minshall, M. E., Shen, W., Cooper, C. C., & Kanis, J. А. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.7.1384 · Cited by 511 · see citing works
Giustina, A. (1998) · Endocrine Reviews · doi:10.1210/er.19.6.717 · Cited by 489 · see citing works
Self-citationFleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479 · see citing works
The Insulin-Like Growth Factor-Binding Protein (IGFBP) Superfamily
Hwa, V. (1999) · Endocrine Reviews · doi:10.1210/er.20.6.761 · Cited by 466 · see citing works
Effects of Testosterone Replacement in Hypogonadal Men
Snyder, P. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2670 · Cited by 464 · see citing works
Lee, S.-K., & Lorenzo, J. A. (1999) · Endocrinology · doi:10.1210/endo.140.8.6887 · Cited by 464 · see citing works
Xiao, G., Gopalakrishnan, R., Jiang, D., Reith, E., Benson, M. D., & Franceschi, R. T. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.101 · Cited by 457 · see citing works
Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., & Onyia, J. E. (2001) · Endocrinology · doi:10.1210/endo.142.9.8356 · Cited by 428 · see citing works
Pérez-Mayorga, M., Gromoll, J., Behre, H. M., Gassner, C., Nieschlag, E., & Simoni, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6789 · Cited by 425 · see citing works
Structural Variants of Prolactin: Occurrence and Physiological Significance
Sinha, Y. N. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-3-354 · Cited by 425 · see citing works
Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids
Kousteni, S., Chen, J.-R., Bellido, T., Han, L., Ali, A. A., O'Brien, C. A., Plotkin, L., Fu, Q., Mancino, A. T., Wen, Y., et al. (2002) · Science · doi:10.1126/science.1074935 · Cited by 420 · see citing works
Decreased spinal mineral content in amenorrheic women
Cann, C. E. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340290040017 · Cited by 409 · see citing works
Osteoporosis in Men with Idiopathic Hypogonadotropic Hypogonadism
Finkelstein, J. S., KLIBANSKI, A., NEER, R. M., GREENSPAN, S. L., ROSENTHAL, D. I., & CROWLEY, W. F. (1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-106-3- · Cited by 407 · see citing works
Expert consensus document: A consensus on the medical treatment of acromegaly
Giustina, A., Chanson, P., Kleinberg, D. L., Bronstein, M. D., Clemmons, D. R., Klibanski, A., van der Lely, A. J., Strasburger, C. J., Lamberts, S. W. J., Ho, K. K. Y., et al. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.21 · Cited by 407 · see citing works
Self-citationValassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C. J., Chanson, P., Wass, J. A. H., Chabre, O., Pfeifer, M., Feelders, R. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0272 · Cited by 402 · see citing works
Gadelha, M. R., Bronstein, M. D., Brue, T. C., Coculescu, M., Fleseriu, M., Guitelman, M. A., Pronin, V. S., Raverot, G., Shimon, I., Lievre, K. K., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70169-x · Cited by 395 · see citing works
Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate
Fan, Y., Hanai, J., Le, P. T., Bi, R., Maridas, D. E., DeMambro, V., Figueroa, C. A., Kır, S., Zhou, X., Mannstadt, M., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.01.001 · Cited by 392 · see citing works
Effect of insulinlike growth factor I on DNA and protein synthesis in cultured rat calvaria.
CANALIS, E. M. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109908 · Cited by 390 · see citing works
Lai, C.-F., Chaudhary, L. R., Fausto, A., Halstead, L. R., Ory, D. S., Avioli, L. V., & Cheng, S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010021200 · Cited by 381 · see citing works
Simoni, M. (1997) · Endocrine Reviews · doi:10.1210/er.18.6.739 · Cited by 380 · see citing works
PTH Differentially Regulates Expression of RANKL and OPG
Huang, J. C., Sakata, T., Pfleger, L. L., Bencsik, M., Halloran, B. P., Bikle, D. D., & Nissenson, R. A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301226 · Cited by 379 · see citing works
Ernst, M., Heath, J. K., & Rodan, G. A. (1989) · Endocrinology · doi:10.1210/endo-125-2-825 · Cited by 369 · see citing works
Glucocorticoid-induced osteoporosis: an update
Mazziotti, G., Angeli, A., Bilezikian, J. P., Canalis, E., & Giustina, A. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.009 · Cited by 362 · see citing works
Self-citationAngeli, A., Guglielmi, G., Dovio, A., Capelli, G., de Feo, D., Giannini, S., Giorgino, R., Moro, L., & Giustina, A. (2006) · Bone · doi:10.1016/j.bone.2006.02.005 · Cited by 361 · see citing works
Self-citationDecreased Bone Density in Hyperprolactinemic Women
Klibanski, A., Neer, R. M., Beitins, I. Z., Ridgway, E. C., Zervas, N. T., & McArthur, J. W. (1980) · New England Journal of Medicine · doi:10.1056/nejm198012253032605 · Cited by 358 · see citing works
Lane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., & Bonewald, L. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051103 · Cited by 355 · see citing works
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
Kopchick, J. J., Parkinson, C., Stevens, E. C., & Trainer, P. J. (2002) · Endocrine Reviews · doi:10.1210/er.2001-0022 · Cited by 350 · see citing works
Ohlsson, C. (1998) · Endocrine Reviews · doi:10.1210/er.19.1.55 · Cited by 346 · see citing works
Reduced bone mineral density in patients with adult onset growth hormone deficiency
Holmes, S. J., Economou, G., Whitehouse, R. W., Adams, J. E., & Shalet, S. M. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.3.8126140 · Cited by 340 · see citing works
Schneider, H. J., Aimaretti, G., Kreitschmann-Andermahr, I., Stalla, G.-K., & Ghigo, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60673-4 · Cited by 336 · see citing works
MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management
Mirza, F., & CANALIS, E. M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0118 · Cited by 334 · see citing works
Myers, M. G., Sun, X., Cheatham, B., Jachna, B. R., Glasheen, E. M., Backer, J., & White, M. F. (1993) · Endocrinology · doi:10.1210/endo.132.4.8384986 · Cited by 333 · see citing works
Santos, C. D., Essioux, L., Teinturier, C., Tauber, M., Goffin, V., & Bougneres, P. F. (2004) · Nature Genetics · doi:10.1038/ng1379 · Cited by 325 · see citing works
A consensus on the diagnosis and treatment of acromegaly complications
Melmed, S. K., Casanueva, F. F., Klibanski, A., Bronstein, M. D., Chanson, P., Lamberts, S. W. J., Strasburger, C. J., Wass, J. A. H., & Giustina, A. (2012) · Pituitary · doi:10.1007/s11102-012-0420-x · Cited by 324 · see citing works
Self-citationThe Effect of Pregnancy on Bone Density and Bone Turnover
Naylor, K. E., Iqbal, P., Fledelius, C., Fraser, R. B., & Eastell, R. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.129 · Cited by 315 · see citing works
On behalf of The Pituitary Society, E. G. O. P. T., Casanueva, F. F., Barkan, A. L., Buchfelder, M., Klibanski, A., Laws, E. R., Loeffler, J. S., Melmed, S. K., Mortini, P., Wass, J. A. H., et al. (2017) · Pituitary · doi:10.1007/s11102-017-0838-2 · Cited by 315 · see citing works
Self-citationKaufman, J., Taelman, P., Vermeulen, A., & Vandeweghe, M. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.1.1727808 · Cited by 314 · see citing works
Carbonare, L. D., Arlot, M. E., Chavassieux, P. M., Roux, J. P., Portero, N. R., & Meunier, P. J. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.1.97 · Cited by 309 · see citing works
Buckley, L. M., Leib, E. S., Cartularo, K. S., Vacek, P. M., & Cooper, S. M. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-12-199612150-00004 · Cited by 309 · see citing works
Hyperthyroidism, Bone Mineral, and Fracture Risk—A Meta-Analysis
Vestergaard, P., & Mosekilde, L. (2003) · Thyroid · doi:10.1089/105072503322238854 · Cited by 306 · see citing works
The Role of Estrogen in the Control of Rat Osteocyte Apoptosis
Tomkinson, A., Gevers, E. F., Wit, J. M., REEVE, J., & Noble, B. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.8.1243 · Cited by 302 · see citing works
Bone turnover markers and bone density across the menopausal transition.
Ebeling, P. R., Atley, L. M., Guthrie, J. R., Burger, H., Dennerstein, L., Hopper, J. L., & Wark, J. D. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784098 · Cited by 302 · see citing works
Ammirati, M., Wei, L., & Ciric, I. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-303194 · Cited by 302 · see citing works
Central Hypothyroidism: Pathogenic, Diagnostic, and Therapeutic Challenges
Persani, L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1616 · Cited by 295 · see citing works
Notch Signaling and the Skeleton.
Zanotti, S., & Canalis, E. (2016) · Endocrine reviews · doi:10.1210/er.2016-1002 · Cited by 283 · see citing works
Hadji, P., Aapro, M., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J., Zillikens, M. C., Glüer, C., de Villiers, T., Baber, R., et al. (2017) · Journal of bone oncology · doi:10.1016/j.jbo.2017.03.001 · Cited by 281 · see citing works
Playford, M. P., Bicknell, D., Bodmer, W. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210394297 · Cited by 279 · see citing works
Beck‐Peccoz, P., Lania, A. G., Beckers, A. M., Chatterjee, K., & Wémeau, J.-L. (2013) · European Thyroid Journal · doi:10.1159/000351007 · Cited by 279 · see citing works
Increased fracture frequency in adult patients with hypopituitarism and GH deficiency
Rosen, T., Wilhelmsen, L., Landin-Wilhelmsen, K., Lappas, G., & Bengtsson, B. (1997) · European Journal of Endocrinology · doi:10.1530/eje.0.1370240 · Cited by 277 · see citing works
Boscaro, M., Ludlam, W., Atkinson, B., Glusman, J., Petersenn, S., Reincke, M., Snyder, P. J., Tabarin, A., Biller, B., Findling, J., et al. (2009) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2008-1008 · Cited by 276 · see citing works
Baum, H. B. A., Biller, B. M. K., Finkelstein, J. S., Cannistraro, K. B., Oppenheim, D. S., Schoenfeld, D., Hoskins, T. A., Wittink, H. M., & Klibanski, A. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-11-199612010-00003 · Cited by 275 · see citing works
Kousteni, S., Li, H., Chen, J., Almeida, M., Plotkin, L. I., Bellido, T., & Manolagas, S. C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17261 · Cited by 272 · see citing works
Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts
Ohnaka, K., Tanabe, M., Kawate, H., Nawata, H., & Takayanagi, R. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.117 · Cited by 270 · see citing works
Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover
Ogata, N., Chikazu, D., Kubota, N., Terauchi, Y., Tobe, K., Azuma, Y., Ohta, T., Kadowaki, T., Nakamura, K., & Kawaguchi, H. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9017 · Cited by 270 · see citing works
Higham, C. E., Johannsson, G., & Shalet, S. M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30053-8 · Cited by 269 · see citing works
Wüster, C., Abs, R., Bengtsson, B.-Å., Bennmarker, H., Feldt-Rasmussen, U., Hernberg-Ståhl, E., Monson, J. P., Westberg, B., & Wilton, P. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.398 · Cited by 267 · see citing works
Boisclair, Y. R., Rhoads, R. P., Ueki, I., Wang, J., & Ooi, G. T. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1700063 · Cited by 263 · see citing works
Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
Pétrossians, P., Daly, A., Natchev, Е., et al. (2017) · Endocrine Related Cancer · doi:10.1530/erc-17-0253 · Cited by 263 · see citing works
Gender-Related Differences in the Presentation and Course of Cushing’s Disease
Giraldi, F. P., Moro, M., & Cavagnini, F. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021518 · Cited by 260 · see citing works
Johannsson, G., Rosén, T., Bosaeus, I. G., Sjöström, L., & Bengtsson, B. ‐. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768843 · Cited by 260 · see citing works
Drug-induced Osteoporosis: Mechanisms and Clinical Implications
Mazziotti, G., CANALIS, E. M., & Giustina, A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.02.028 · Cited by 259 · see citing works
Self-citationThe Australian Multicenter Trial of Growth Hormone (GH) Treatment in GH-Deficient Adults
Cuneo, R. C., Judd, S., Wallace, J. D., Perry‐Keene, D. A., Burger, H., Lim-Tio, S. S., Strauss, B. J., Stockigt, J. R., Topliss, D. J., ALFORD, F. P., et al. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.1.4482 · Cited by 259 · see citing works
Hyperprolactinemia and Prolactinomas
Mancini, T., Casanueva, F. F., & Giustina, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.013 · Cited by 257 · see citing works
Self-citationInsulin-like growth factor-I supports formation and activation of osteoclasts
Mochizuki, H., Hakeda, Y., Wakatsuki, N., et al. (1992) · Endocrinology · doi:10.1210/endo.131.3.1505451 · Cited by 250 · see citing works
Bone homeostasis in growth hormone receptor–null mice is restored by IGF-I but independent of Stat5
Sims, N. A., Clément-Lacroix, P., Ponte, F. D., Bouali, Y., Binart, N., Moriggl, R., Goffin, V., Coschigano, K. T., Gaillard-Kelly, M., Kopchick, J. J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10753 · Cited by 249 · see citing works
Marinis, L. D., Bonadonna, S., Bianchi, A., Maira, G., & Giustina, A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0288 · Cited by 249 · see citing works
Self-citationOsteoporosis in Men with Hyperprolactinemic Hypogonadism
Greenspan, S. L., NEER, R. M., Ridgway, E. C., & KLIBANSKI, A. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-6-777 · Cited by 249 · see citing works
Hormone Predictors of Bone Mineral Density Changes during the Menopausal Transition
Sowers, M. R., Jannausch, M. L., McConnell, D. S., Little, R. J. A., Greendale, G. A., Finkelstein, J. S., Neer, R. M., Johnston, J. M., & Ettinger, B. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1836 · Cited by 247 · see citing works
The C/EBP Family of Transcription Factors
Wedel, A., & Lömsziegler-Heitbrock, H. W. (1995) · Immunobiology · doi:10.1016/s0171-2985(11)80541-3 · Cited by 245 · see citing works
Kamenický, P., Mazziotti, G., Lombès, M., Giustina, A., & Chanson, P. (2013) · Endocrine Reviews · doi:10.1210/er.2013-1071 · Cited by 243 · see citing works
Self-citationPeeters, R. P., van Toor, H., Klootwijk, W., de Rijke, Y. B., Kuiper, G. G. J. M., Uitterlinden, A. G., & Visser, T. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021592 · Cited by 242 · see citing works
Kousteni, S., Li, H., Chen, J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317261 · Cited by 237 · see citing works
Recent advances in growth hormone signaling
Lanning, N. J., & Carter‐Su, C. (2006) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9025-5 · Cited by 232 · see citing works
Juul, A., Main, K. M., Blum, W. F., Lindholm, J., Ranke, M. B., & Skakkebæk, N. E. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03788.x · Cited by 232 · see citing works
Götherström, G., Svensson, J., Koranyi, J., Alpsten, M., Bosaeus, I. G., Bengtsson, B. ‐., & Johannsson, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.10.7887 · Cited by 228 · see citing works
Iqbal, J., Sun, L., Kumar, T., Blair, H., & Zaidi, M. (2006) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0606805103 · Cited by 222 · see citing works
O’Halloran, D., Tsatsoulis, A. A., Whitehouse, R. W., Holmes, S. J., Adams, J. E., & Shalet, S. M. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.5.8496328 · Cited by 218 · see citing works
Murray, R. D., & Melmed, S. K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0027 · Cited by 217 · see citing works
Kassem, M. S., Blum, W. F., Risteli, J., Mosekilde, L., & Eriksen, E. F. (1993) · Calcified Tissue International · doi:10.1007/bf00298723 · Cited by 215 · see citing works
Vertebral fracture epidemiology
Wasnich, R. D. (1996) · Bone · doi:10.1016/8756-3282(95)00499-8 · Cited by 214 · see citing works
Shalhoub, V., Conlon, D., Stein, G. S., Lian, J. B., Tassinari, M. S., Quinn, C. O., & Partridge, N. C. (1992) · Journal of Cellular Biochemistry · doi:10.1002/jcb.240500411 · Cited by 214 · see citing works
Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss
Lukert, B. P., Johnson, B. E., & Robinson, R. G. (1992) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650070909 · Cited by 211 · see citing works
Marians, R. C., Ng, L., Blair, H. C., Unger, P. D., Graves, P. N., & Davies, T. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242322099 · Cited by 209 · see citing works
Glucocorticoids and the regulation of growth hormone secretion
Mazziotti, G., & Giustina, A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.5 · Cited by 206 · see citing works
Self-citationGesty‐Palmer, D., Flannery, P., Yuan, L., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000071 · Cited by 205 · see citing works
Increase in Bone Mass after Treatment of Hyperprolactinemic Amenorrhea
Klibanski, A., & Greenspan, S. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608283150903 · Cited by 205 · see citing works
The TSH receptor reveals itself
Davies, T. F., Marians, R. C., & Latif, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16234 · Cited by 203 · see citing works
Consequences of childhood-onset growth hormone deficiency for adult bone mass
de Boer, H., Blok, G. J., van Lingen, A., Teule, G. J. J., Lips, P. T. A. M., & van der Veen, E. A. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090822 · Cited by 203 · see citing works
Reduced bone mineral content in adult patients with growth hormone deficiency
Rosén, T., HANSSON, T. H., Granhed, H., Szücs, J., & Bengtsson, B. (1993) · European Journal of Endocrinology · doi:10.1530/acta.0.1290201 · Cited by 203 · see citing works
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
Giustina, A., Mazziotti, G., Torri, V., Spinello, M., Floriani, I., & Melmed, S. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036411 · Cited by 202 · see citing works
Self-citationRole of IGF-I Signaling in Regulating Osteoclastogenesis
Wang, Y., Nishida, S., Elalieh, H. Z., Long, R. K., Halloran, B. P., & Bikle, D. D. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060610 · Cited by 199 · see citing works
Colao, A., Somma, C. D., Pivonello, R., Loche, S., Aimaretti, G., Cerbone, G., Faggiano, A., Corneli, G., Ghigo, E., & Lombardi, G. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.6.5742 · Cited by 197 · see citing works
Saggese, G., Baroncelli, G. I., Bertelloni, S., Cinquanta, L., & Nero, G. D. (1993) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)83484-5 · Cited by 195 · see citing works
Clément-Lacroix, P., Ormandy, C. J., Lepescheux, L., Ammann, P., Damotte, D., Goffin, V., Bouchard, B., Amling, M., Gaillard-Kelly, M., Binart, N., et al. (1999) · Endocrinology · doi:10.1210/endo.140.1.6436 · Cited by 193 · see citing works
Gent, J., van Kerkhof, P., Roza, M., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152294299 · Cited by 192 · see citing works
Importance of Gonadal Steroids to Bone Mass in Men with Hyperprolactinemic Hypogonadism
Greenspan, S. L., Oppenheim, D. S., & Klibanski, A. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-7-526 · Cited by 190 · see citing works
Effect of testosterone replacement on trabecular architecture in hypogonadal men
Benito, M., Vasilic, B., Wehrli, F. W., Bunker, B., Wald, M., Gomberg, B., Wright, A. C., Zemel, B., Cucchiara, A., & Snyder, P. J. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050606 · Cited by 188 · see citing works
Bonadonna, S., Mazziotti, G., Nuzzo, M., Bianchi, A., Fusco, A., Marinis, L. D., & Giustina, A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050603 · Cited by 187 · see citing works
Self-citationInhibin at 90: From Discovery to Clinical Application, a Historical Review
Makanji, Y., Zhu, J., Mishra, R. K., Holmquist, C., Wong, W. P. S., Schwartz, N. B., Mayo, K. E., & Woodruff, T. K. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1003 · Cited by 187 · see citing works
Hoffman, A. R., Kuntze, J. E., Baptista, J., Baum, H. B. A., Baumann, G. P., Biller, B. M. K., Clark, R. V., Cook, D., Inzucchi, S. E., Kleinberg, D., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030346 · Cited by 185 · see citing works
Bone Turnover, Bone Mineral Density, and Fracture Risk in Acromegaly: A Meta-Analysis
Mazziotti, G., Biagioli, E. C., Maffezzoni, F., Spinello, M., Serra, V., Maroldi, R., Floriani, I., & Giustina, A. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2937 · Cited by 182 · see citing works
Self-citationBone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.
Hermus, A., Smals, A., Swinkels, L., Huysmans, D., Pieters, G., Sweep, C., Corstens, F., & Kloppenborg, P. (1995) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jcem.80.10.7559865 · Cited by 181 · see citing works
Effects of Prolactin and Estrogen Deficiency in Amenorrheic Bone Loss*
Klibanski, A., Biller, B. M. K., Rosenthal, D. I., Schoenfeld, D., & SAXE, V. C. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-1-124 · Cited by 179 · see citing works
Seriwatanachai, D., Thongchote, K., Charoenphandhu, N., Pandaranandaka, J., Tudpor, K., Teerapornpuntakit, J., Suthiphongchai, T., & Krishnamra, N. (2007) · Bone · doi:10.1016/j.bone.2007.11.008 · Cited by 176 · see citing works
Slootweg, M. C. (1993) · Hormone and Metabolic Research · doi:10.1055/s-2007-1002115 · Cited by 175 · see citing works
IV. Meta-Analysis of Raloxifene for the Prevention and Treatment of Postmenopausal Osteoporosis
Cranney, A., Tugwell, P., Zytaruk, N. L., Robinson, V. A., Weaver, B., Adachi, J. D., Wells, G., Shea, B., Guyatt, G. H., & The Osteoporosis Methodology Group (2002) · Endocrine Reviews · doi:10.1210/er.2001-4002 · Cited by 172 · see citing works
Vertebral Fractures in Patients With Acromegaly: A 3-Year Prospective Study
Mazziotti, G., Bianchi, A., Porcelli, T., Mormando, M., Maffezzoni, F., Cristiano, A., Giampietro, A., De Marinis, L., & Giustina, A. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1460 · Cited by 172 · see citing works
Self-citationBone Density in Amenorrheic Women with and without Hyperprolactinemia*
Schlechte, J., Sherman, B. M., & Martin, R. (1983) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-56-6-1120 · Cited by 170 · see citing works
The Bone Remodeling Compartment: A Circulatory Function for Bone Lining Cells
Parfitt, A. M. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.9.1583 · Cited by 169 · see citing works
Prevalence of Vertebral Fractures in Men with Acromegaly
Mazziotti, G., Bianchi, A., Bonadonna, S., Cimino, V., Patelli, I., Fusco, A., Pontecorvi, A., De Marinis, L., & Giustina, A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0791 · Cited by 169 · see citing works
Self-citationThe accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis
Marques, A., Ferreira, R. J. O., Santos, E. J. F., Loza, E., Carmona, L., & da Silva, J. A. P. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-207907 · Cited by 168 · see citing works
The TSH receptor reveals itself
Davies, T. F., Marians, R. C., & Latif, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216234 · Cited by 166 · see citing works
Smith, E., & Frenkel, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406294200 · Cited by 163 · see citing works
Sowers, M. R., Finkelstein, J. S., Ettinger, B. B., Bondarenko, I., Neer, R. M., Cauley, J. A., Sherman, S., & Greendale, G. A. (2003) · Osteoporosis International · doi:10.1007/s00198-002-1307-x · Cited by 163 · see citing works
Tauchmanovà, L., Pivonello, R., Somma, C. D., Rossi, R., Martino, M. D. D., Camera, L., Klain, M., Salvatore, M., Lombardi, G., & Colao, A. (2006) · Journal of Clinical Endocrinology and Metabolism · doi:10.1210/jc.2005-0582 · Cited by 162 · see citing works
Utility of the trabecular bone score (TBS) in secondary osteoporosis
Ulivieri, F. M., Silva, B. C., Sardanelli, F., Hans, D., Bilezikian, J. P., & Caudarella, R. (2014) · Endocrine · doi:10.1007/s12020-014-0280-4 · Cited by 161 · see citing works
Clinical, quality of life, and economic value of acromegaly disease control
Ben-Shlomo, A., Sheppard, M. C., Stephens, J., Pulgar, S. J., & Melmed, S. K. (2011) · Pituitary · doi:10.1007/s11102-011-0310-7 · Cited by 160 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Consensus on diagnosis and management of Cushing's disease: a guideline update
Fleseriu, M., Auchus, R., Bancos, I., Ben-Shlomo, A., Bertherat, J., Biermasz, N. R., Boguszewski, C. L., Bronstein, M. D., Buchfelder, M., Carmichael, J. D., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00235-7 · Cited by 953 · see citing works
Self-citationA Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update
Giustina, A., Barkan, A. L., Beckers, A. M., Biermasz, N. R., Biller, B. M. K., Boguszewski, C. L., Bolanowski, M., Bonert, V. S., Bronstein, M. D., Casanueva, F. F., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz096 · Cited by 371 · see citing works
Self-citationSystemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 368 · see citing works
Clinical Biology of the Pituitary Adenoma
Melmed, S. K., Kaiser, U. B., Lopes, M. B. S., Bertherat, J. Y., Syro, L. V., Raverot, G., Reincke, M., Johannsson, G., Beckers, A. M., Fleseriu, M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac010 · Cited by 342 · see citing works
Self-citationAcromegaly: pathogenesis, diagnosis, and management
Fleseriu, M., Langlois, F., Lim, D. S. T., Varlamov, E. V., & Melmed, S. K. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00244-3 · Cited by 285 · see citing works
Reincke, M., & Fleseriu, M. (2023) · JAMA · doi:10.1001/jama.2023.11305 · Cited by 273 · see citing works
Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults
Melmed, S. K. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1817346 · Cited by 175 · see citing works
Samperi, I., Lithgow, K. C., & Karavitaki, N. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122203 · Cited by 119 · see citing works
Skeletal disorders associated with the growth hormone–insulin-like growth factor 1 axis
Mazziotti, G., Lania, A. G., & CANALIS, E. M. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00649-8 · Cited by 108 · see citing works
Self-citationFrara, S., Allora, A., Castellino, L., di Filippo, L., Loli, P., & Giustina, A. (2021) · Pituitary · doi:10.1007/s11102-021-01148-1 · Cited by 97 · see citing works
Self-citationPituitary Tumors Centers of Excellence.
Frara, S., Rodríguez-Carnero, G., Formenti, A. M., Olmos, M. M., Giustina, A., & Casanueva, F. (2020) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2020.05.010 · Cited by 62 · see citing works
Self-citationPotential mechanisms linking psychological stress to bone health
Ng, J.-S., & Chin, K.-Y. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.50680 · Cited by 66 · see citing works
Bone quality in endocrine diseases: determinants and clinical relevance
Cianferotti, L., Cipriani, C., Corbetta, S., Corona, G., Defeudis, G., Lania, A. G., Messina, C., Napoli, N., & Mazziotti, G. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02056-w · Cited by 65 · see citing works
Self-citationDIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders
Eller-Vainicher, C., Falchetti, A., Gennari, L., Cairoli, E., Bertoldo, F., Vescini, F., Scillitani, A., & Chiodini, I. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0991 · Cited by 64 · see citing works
Chiloiro, S., Giampietro, A., Frara, S., Bima, C., Donfrancesco, F., Fleseriu, C. M., Pontecorvi, A., Giustina, A., Fleseriu, M., Marinis, L. D., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz054 · Cited by 64 · see citing works
Self-citationMANAGEMENT OF ENDOCRINE DISEASE: Bone disorders associated with acromegaly: mechanisms and treatment
Mazziotti, G., Lania, A. G., & CANALIS, E. M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0184 · Cited by 63 · see citing works
Self-citationdi Filippo, L., Doga, M., Resmini, E., & Giustina, A. (2020) · Pituitary · doi:10.1007/s11102-020-01041-3 · Cited by 59 · see citing works
Self-citationVarlamov, E. V., Langlois, F., Vila, G., & Fleseriu, M. (2021) · European Journal of Endocrinology · doi:10.1530/eje-20-1309 · Cited by 58 · see citing works
Bone-organ axes: bidirectional crosstalk
Deng, A.-F., Wang, F., Wang, S., Zhang, Y., Bai, L., & Su, J. (2024) · Military Medical Research · doi:10.1186/s40779-024-00540-9 · Cited by 60 · see citing works
Acromegaly and Vertebral Fractures: Facts and Questions
Giustina, A. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.01.011 · Cited by 49 · see citing works
Self-citationSchoeb, M., Hamdy, N. A. T., Malgo, F., Winter, E. M., & Appelman‐Dijkstra, N. M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00015 · Cited by 46 · see citing works
Sagna, Y., Courtillot, C., Drabo, J. Y., Tazi, A., Donadieu, J., Idbaïh, A., Aubart, F. C., Amoura, Z., Haroche, J., & Touraine, P. A. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0177 · Cited by 45 · see citing works
Effects of Medical Treatment of Prostate Cancer on Bone Health
Formenti, A. M., Volta, A. D., di Filippo, L., Berruti, A., & Giustina, A. (2021) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.12.004 · Cited by 45 · see citing works
Self-citationFrara, S., Uygur, M. M., di Filippo, L., Doga, M., Losa, M., Santoro, S., Mortini, P., & Giustina, A. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac183 · Cited by 43 · see citing works
Self-citationHan, S., Kuang, M., Sun, C., Wang, H., Wang, D., & Liu, Q. (2020) · Aging · doi:10.18632/aging.103560 · Cited by 42 · see citing works
Osteopathy in mild adrenal Cushing’s syndrome and Cushing disease
Frara, S., Allora, A., di Filippo, L., Formenti, A. M., Loli, P., Polizzi, E., Tradati, D., Ulivieri, F. M., & Giustina, A. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101515 · Cited by 43 · see citing works
Self-citationAcromegaly and Bone: An Update
Giustina, A. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.601 · Cited by 42 · see citing works
Self-citationMazziotti, G., Battista, C., Maffezzoni, F., Chiloiro, S., Ferrante, E., Prencipe, N., Grasso, L. F. S., Gatto, F., Olivetti, R., Arosio, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa363 · Cited by 41 · see citing works
Self-citationFrara, S., Loli, P., Allora, A., Santini, C., di Filippo, L., Mortini, P., Fleseriu, M., & Giustina, A. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09672-y · Cited by 38 · see citing works
Self-citationMortini, P., Nocera, G., Roncelli, F., Losa, M., Formenti, A. M., & Giustina, A. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09564-7 · Cited by 38 · see citing works
Self-citationAndereggen, L., Frey, J., Andres, R. H., Luedi, M. M., Widmer, H. R., Beck, J., Mariani, L., & Christ, E. (2021) · Scientific Reports · doi:10.1038/s41598-021-84606-x · Cited by 38 · see citing works
Complications and Comorbidities of Acromegaly—Retrospective Study in Polish Center
Rolla, M., Jawiarczyk-Przybyłowska, A., Halupczok-Żyła, J., Kałużny, M., Konopka, B. M., Błoniecka, I., Zieliński, G., & Bolanowski, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.642131 · Cited by 38 · see citing works
Understanding and managing secondary osteoporosis
Colangelo, L., Biamonte, F., Pepe, J., Cipriani, C., & Minisola, S. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1575727 · Cited by 36 · see citing works
Risk of vertebral fractures in hypoparathyroidism
Formenti, A. M., Tecilazich, F., Giubbini, R., & Giustina, A. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09507-x · Cited by 35 · see citing works
Self-citationGatto, F., Campana, C., Cocchiara, F., et al. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09506-y · Cited by 33 · see citing works
New tools for bone health assessment in secreting pituitary adenomas
Uygur, M. M., Frara, S., di Filippo, L., & Giustina, A. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.01.006 · Cited by 33 · see citing works
Self-citationTrabecular bone score and bone mineral density in patients with long‐term controlled acromegaly
Calatayud, M., Martín, L. P., Librizzi, M. S., Lora, D., Mendez, V. G., Aramendi, M., Diaz‐Guerra, G. M., & Hawkins, F. G. (2021) · Clinical Endocrinology · doi:10.1111/cen.14439 · Cited by 32 · see citing works
Volta, A. D., Mazziotti, G., Maffezzoni, F., Grisanti, S., Palumbo, C., Pedersini, R., Maroldi, R., & Berruti, A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00434 · Cited by 31 · see citing works
Self-citationCellini, M., Biamonte, E., Mazza, M., Trenti, N., Ragucci, P., Milani, D., Ferrante, E., Rossini, Z., Lavezzi, E., Sala, E., et al. (2020) · Neuroendocrinology · doi:10.1159/000511811 · Cited by 31 · see citing works
Self-citationNovel approaches to bone comorbidity in Cushing’s disease: an update
Frara, S., di Filippo, L., Doga, M., Loli, P., Casanueva, F. F., & Giustina, A. (2022) · Pituitary · doi:10.1007/s11102-022-01252-w · Cited by 32 · see citing works
Self-citationBioletto, F., Barale, M., Prencipe, N., Berton, A. M., Parasiliti‐Caprino, M., Gasco, V., Ghigo, E., Massimo, P., & Grottoli, S. (2022) · Neuroendocrinology · doi:10.1159/000528199 · Cited by 31 · see citing works
High Prevalence of Radiological Vertebral Fractures in Patients With TSH-Secreting Pituitary Adenoma
Frara, S., Losa, M., Doga, M., Formenti, A. M., Mortini, P., Mazziotti, G., & Giustina, A. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00091 · Cited by 31 · see citing works
Self-citationVena, W., Pizzocaro, A., Indirli, R., Amer, M., Maffezzoni, F., Delbarba, A., Leonardi, L., Balzarini, L., Ulivieri, F. M., Ferlin, A., et al. (2020) · Andrology · doi:10.1111/andr.12841 · Cited by 30 · see citing works
Self-citationLöffler, J., Noom, A., Ellinghaus, A., Dienelt, A., Kempa, S., & Duda, G. N. (2023) · Communications Biology · doi:10.1038/s42003-023-04652-1 · Cited by 30 · see citing works
Chiloiro, S., Frara, S., Gagliardi, I., Bianchi, A., Giampietro, A., Medici, M., Allora, A., di Filippo, L., Ambrosio, M. R., Pontecorvi, A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad493 · Cited by 29 · see citing works
Self-citationThe Oxytocin System and Implications for Oxytocin Deficiency in Hypothalamic-Pituitary Disease
Aulinas, A., & Lawson, E. A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf008 · Cited by 30 · see citing works
High bone marrow fat in patients with Cushing’s syndrome and vertebral fractures
Ferraù, F., Giovinazzo, S., Messina, E., Tessitore, A., Vinci, S. L., Mazziotti, G., Lania, A. G., Granata, F., & Cannavò, S. (2019) · Endocrine · doi:10.1007/s12020-019-02034-4 · Cited by 29 · see citing works
Self-citationDziałach, Ł., Sobolewska, J., Żak, Z., Respondek, W., & Witek, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1338345 · Cited by 27 · see citing works
Neumeier, M. S., Homan, S., Vetter, S., Seifritz, E., Kane, J. M., Huhn, M., Leucht, S., & Homan, P. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab078 · Cited by 22 · see citing works
Determinants of skeletal fragility in acromegaly: a systematic review and meta-analysis
de Moura, C. R., Lopes, S. G. D. C., & Monteiro, A. M. (2022) · Pituitary · doi:10.1007/s11102-022-01256-6 · Cited by 25 · see citing works
Vena, W., Carrone, F., Delbarba, A., Akpojiyovbi, O., Pezzaioli, L. C., Facondo, P., Cappelli, C., Leonardi, L., Balzarini, L., Farina, D., et al. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01901-8 · Cited by 25 · see citing works
Self-citationEffect of Hyperprolactinemia on Bone Metabolism: Focusing on Osteopenia/Osteoporosis
Yun, S. J., Sang, H., Park, S. Y., & Chin, S. O. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031474 · Cited by 24 · see citing works
New insights into the vitamin D/PTH axis in endocrine-driven metabolic bone diseases
di Filippo, L., Bilezikian, J. P., CANALIS, E. M., Terenzi, U., & Giustina, A. (2024) · Endocrine · doi:10.1007/s12020-024-03784-6 · Cited by 22 · see citing works
Self-citationInsulin signaling in the whole spectrum of GH deficiency
Garmes, H., & Castillo, A. R. (2019) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000188 · Cited by 19 · see citing works
Mazziotti, G., Vena, W., Pedersini, R., Piccini, S., Morenghi, E., Cosentini, D., Zucali, P. A., Torrisi, R., Sporeni, S., Simoncini, E., et al. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100421 · Cited by 22 · see citing works
Self-citationTrabecular bone score, bone marrow fat and vertebral fractures in cushing syndrome
Ferraù, F., Giovinazzo, S., Alessi, Y., Catalano, A., Tessitore, A., Mormina, E., Bellone, F., Giuffrida, G., Paola, G., Cotta, O. R., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03318-6 · Cited by 21 · see citing works
Self-citationValassi, E., García‐Giralt, N., Malouf, J., Crespo, I., Llauger, J., Díez‐Pérez, A., & Webb, S. M. (2019) · Endocrine Connections · doi:10.1530/ec-18-0482 · Cited by 20 · see citing works
The acromegalic spine: fractures, deformities and spinopelvic balance
Oliveira, B. D. A., de Araújo, B. M. F., dos Santos, T. M., Ongaratti, B. R., Leães, C. G. S., Ferreira, N. P., Pereira‐Lima, J. F. S., & Oliveira, M. D. C. (2019) · Pituitary · doi:10.1007/s11102-019-00991-7 · Cited by 20 · see citing works
Aulinas, A., Guarda, F. J., Yu, E. W.-Y., Haines, M. S., Asanza, E., Silva, L. E., Tritos, N. A., Verbalis, J. G., Miller, K. K., & Lawson, E. A. (2020) · Neuroendocrinology · doi:10.1159/000506638 · Cited by 20 · see citing works
Ferrière, A., & Tabarin, A. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104091 · Cited by 19 · see citing works
Skeletal health in patients with differentiated thyroid carcinoma
Cellini, M., Rotondi, M., Tanda, M. L., Piantanida, E., Chiovato, L., Beck‐Peccoz, P., Lania, A. G., & Mazziotti, G. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01359-6 · Cited by 19 · see citing works
Self-citationBone densitometry by radiofrequency echographic multi-spectrometry (REMS) in acromegaly patients
Rolla, M., Halupczok-Żyła, J., Jawiarczyk-Przybyłowska, A., & Bolanowski, M. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2020.0056 · Cited by 21 · see citing works
Direct effects of octreotide on osteoblast cell proliferation and function
Vitali, E., Palagano, E., Schiavone, M. L., Mantovani, G., Sobacchi, C., Mazziotti, G., & Lania, A. G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01740-7 · Cited by 19 · see citing works
Self-citationMusculoskeletal complications of Cushing syndrome
Leszczyńska, D., Szatko, A., Papierska, L., Zgliczyński, W., & Glinicki, P. (2023) · Reumatologia/Rheumatology · doi:10.5114/reum/169889 · Cited by 57 · see citing works
Zdrojowy-Wełna, A., Stachowska, B., & Bolanowski, M. (2024) · Pituitary · doi:10.1007/s11102-024-01427-7 · Cited by 21 · see citing works
Gou, Z., Li, F., Qiao, F., et al. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1162442 · Cited by 18 · see citing works
Godang, K., Lekva, T., Normann, K. R., Olarescu, N. C., Øystese, K. A., Kolnes, A. J., Ueland, T., Bollerslev, J., & Heck, A. (2019) · JBMR Plus · doi:10.1002/jbm4.10240 · Cited by 18 · see citing works
The Negative Impacts of Acromegaly on Bone Microstructure Not Fully Reversible
Duan, L., Yang, S., Wang, L. J., Zhang, Y., Li, R., Yang, H., Zhao, Y., Du, H., Zhai, X., Gong, F., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.738895 · Cited by 18 · see citing works
Skeletal fragility: an emerging complication of Ehlers–Danlos syndrome
Formenti, A. M., Doga, M., Frara, S., Ritelli, M., Colombi, M., Banfi, G., & Giustina, A. (2019) · Endocrine · doi:10.1007/s12020-018-1822-y · Cited by 17 · see citing works
Self-citationPituitary Disorders and COVID-19, Reimagining Care: The Pandemic A Year and Counting
Fleseriu, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.656025 · Cited by 16 · see citing works
Osteosarcopenia in autoimmune cholestatic liver diseases: Causes, management, and challenges
Pugliese, N., Arcari, I., Aghemo, A., Lania, A. G., Lleò, A., & Mazziotti, G. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i14.1430 · Cited by 14 · see citing works
Self-citationPalumbo, C., Volta, A. D., Zamboni, S., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac489 · Cited by 14 · see citing works
Self-citationAdrenal Incidentaloma: Picking out the High-Risk Patients
Dalmazi, G. D. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0713-0598 · Cited by 14 · see citing works
Guidelines on diagnostics and treatment of acromegaly (draft)
Przhiyalkovskaya, E. G., Mokrysheva, N. G., Troshina, E. A., Mel'nichenko, G. A., Dedov, I. I., Antsiferov, M. B., Astafieva, L. I., Bardymova, T. P., Belaya, Z. E., Vagapova, G. R., et al. (2024) · Obesity and metabolism · doi:10.14341/omet13153 · Cited by 13 · see citing works
3D DXA Hip Differences in Patients with Acromegaly or Adult Growth Hormone Deficiency
Gracia‐Marco, L., González-Salvatierra, S., García‐Martin, A., Ubago‐Guisado, E., García-Fontana, B., Gil-Cosano, J. J., & Muñoz‐Torres, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040657 · Cited by 13 · see citing works
Animal Models of Cushing's Syndrome
Nishiyama, M., Iwasaki, Y., & Makino, S. (2022) · Endocrinology · doi:10.1210/endocr/bqac173 · Cited by 15 · see citing works
Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes
Akirov, A., Rudman, Y., & Fleseriu, M. (2024) · Pituitary · doi:10.1007/s11102-024-01391-2 · Cited by 12 · see citing works
Palombo, M. R., & Zedda, M. (2021) · Integrative Zoology · doi:10.1111/1749-4877.12533 · Cited by 12 · see citing works
Skeletal complications in acromegaly
Wydra, A., Stelmachowska‐Banaś, M., & Czajka-Oraniec, I. (2023) · Reumatologia/Rheumatology · doi:10.5114/reum/169918 · Cited by 12 · see citing works
Osteogenesis Hormonal Regulation: Review
Мироманов, А. М., & Аркадьевич, Г. К. (2021) · Traumatology and Orthopedics of Russia · doi:10.21823/2311-2905-1609 · Cited by 11 · see citing works
AMBROSIO, M. R., ALIBERTI, L., GAGLIARDI, I., FRANCESCHETTI, P., & ZATELLI, M. C. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.20.04713-9 · Cited by 11 · see citing works
Mazziotti, G., Rodari, M., Gelardi, F., Tosi, G., Zucali, P. A., Pepe, G., & Chiti, A. (2020) · Endocrine · doi:10.1007/s12020-020-02277-6 · Cited by 10 · see citing works
Self-citationUpdate on vertebral fractures in pituitary diseases: from research to clinical practice
Carrone, F., Ariano, S. A., Piccini, S., Milani, D., Mirani, M., Balzarini, L., Lania, A. G., & Mazziotti, G. (2021) · HORMONES · doi:10.1007/s42000-021-00275-5 · Cited by 10 · see citing works
Self-citationVitamin D in pituitary driven osteopathies
Chiloiro, S., Costanza, F., Riccardi, E., Giampietro, A., Marinis, L. D., Bianchi, A., Pontecorvi, A., & Giustina, A. (2024) · Pituitary · doi:10.1007/s11102-024-01439-3 · Cited by 10 · see citing works
Self-citationPovaliaeva, A. A., Bogdanov, V. P., Pigarova, E. A., Zhukov, A. Y., Dzeranova, L. K., Belaya, Z. E., Rozhinskaya, L. Y., Mel'nichenko, G. A., & Mokrysheva, N. (2021) · Nutrients · doi:10.3390/nu13124329 · Cited by 11 · see citing works
Modern approach to bone comorbidity in prolactinoma
Uygur, M. M., Menotti, S., Santoro, S., & Giustina, A. (2024) · Pituitary · doi:10.1007/s11102-024-01469-x · Cited by 10 · see citing works
Self-citationBone microarchitecture impairment in prolactinoma patients assessed by HR-pQCT
Wang, L., Chen, K., Duan, L., Ke, X., Gong, F., Pan, H., Yang, H., Zhu, H., & Xia, W. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06289-4 · Cited by 9 · see citing works
Sweat and vitamin D status in congenital, lifetime, untreated GH deficiency
Barros-Oliveira, C. S., Salvatori, R., dos Santos, J. S. S., et al. (2019) · Endocrine · doi:10.1007/s12020-019-01998-7 · Cited by 9 · see citing works
van Santen, S. S., Olsson, D. S., Hammarstrand, C., Wijnen, M., Fiocco, M. F., van den Heuvel‐Eibrink, M. M., Johannsson, G., Janssen, J. A. M. J. L., van der Lely, A. J., & Neggers, S. J. C. M. M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa607 · Cited by 9 · see citing works
Pontes, J., Madeira, M., Lima, C. H. D. A., Ogino, L. L., Paranhos‐Neto, F. D. P., de Mendonça, L. M. C., Farias, M. L. F., Kasuki, L., & Gadelha, M. R. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01096-5 · Cited by 9 · see citing works
Root, A. W., & Levine, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00020-8 · Cited by 9 · see citing works
Sun, H., Wu, C., Hu, B., & Xie, G. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2282183 · Cited by 9 · see citing works
Cellini, M., Piccini, S., Ferrante, G., Carrone, F., Olivetti, R., Cicorella, N., Aroldi, M., Pini, D., Centanni, M., Lania, A. G., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01237-1 · Cited by 8 · see citing works
Self-citationLima, T. R. L., Kasuki, L., Gadelha, M. R., et al. (2019) · Journal of Bodywork and Movement Therapies · doi:10.1016/j.jbmt.2019.01.006 · Cited by 8 · see citing works
Chiloiro, S., Mirra, F., Donfrancesco, F., Giampietro, A., Visconti, F., Rossi, L., Pontecorvi, A., Marinis, L. D., & Bianchi, A. (2020) · Protein and Peptide Letters · doi:10.2174/0929866527666200616151105 · Cited by 8 · see citing works
Ceccato, F., Terzolo, M., Gatto, F., Cannavò, S., Bianchi, A., Isidori, A. M., Colao, A. A. L., Ferone, D., Aimaretti, G., Giraldi, F. P., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02758-3 · Cited by 10 · see citing works
Das, L., Laway, B. A., Sahoo, J., Dhiman, V., Singh, P., Rao, S. D., Korbonits, M., Bhadada, S. K., & Dutta, P. R. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07062-z · Cited by 7 · see citing works
Frara, S., Uygur, M. M., Bolamperti, F. M., di Filippo, L., Doga, M., Ferrari, F., Losa, M., Mortini, P., & Giustina, A. (2024) · Pituitary · doi:10.1007/s11102-024-01394-z · Cited by 7 · see citing works
Self-citationSkeletal fragility in pituitary disease: how can we predict fracture risk?
Bioletto, F., Berton, A. M., Barale, M., Aversa, L. S., Sauro, L., Presti, M., Mocellini, F., Sagone, N., Ghigo, E., Massimo, P., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01447-3 · Cited by 7 · see citing works
Vitamin D and hip protectors in osteosarcopenia: a combined hip fracture preventing approach
Giustina, A., & Giustina, A. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09907-8 · Cited by 7 · see citing works
Self-citation
- Authors
- Mazziotti, G., Frara, S., & Giustina, A.
- Affiliations
- Azienda Ospedaliera Carlo Poma (IT)
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Giustina, Andrea
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2018-04-19
- Volume
- 39
- Issue
- 4
- Pages
- 440-488
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2802757031
- Semantic Scholar
- fc2486195e60c7a6d5657d25d8846333318c22bd
- Cited by
- 181
- References
- 648
- Citations by year
- 2026: 13 · 2025: 20 · 2024: 31 · 2023: 20 · 2022: 21 · 2021: 26 · 2020: 23 · 2019: 18 · 2018: 6
- FWCI
- 17.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Pfizer
- Astellas Pharma
- Ipsen
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- pituitary disorders, bone, bone remodeling, bone metabolism, hypopituitarism, Cushing's disease, acromegaly, hyperprolactinemia, secondary osteoporosis, fracture risk, bone mineral density, bone quality
- MeSH terms
- Animals, Humans, Osteoporosis, Pituitary Diseases, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-28.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-28.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review